14-3-3 proteins and the p53 family : a study in keratinocytes by Niemantsverdriet, Maarten
14-3-3 proteins and the p53 family 
a study in keratinocytes 
Maarten Niemantsverdriet 

14-3-3 proteins and the p53 family 
a study in keratinocytes 
Proefschrift
ter verkrijging van de graad 
van Doctor aan de Universiteit Leiden, 
op gezag van Rector Magnificus prof.mr. P.F. van der Heijden, 
volgens besluit van het College voor Promoties 
te verdedigen op donderdag 24 april 2008 
klokke 13.45 uur 
door
Maarten Niemantsverdriet 
Geboren te Hellevoetsluis in 1976 
promotiecommissie:
promotor  : Prof. dr. J. Brouwer 
co-promotor  : Dr. C. Backendorf 
referent  : Prof. dr. H.P. Spaink 
overige leden :  Prof. dr. M.H.M. Noteborn 
: Prof. dr. L.H.F Mullenders 
:  Prof. dr. B. v.d. Water 
Financial support by: 
Tebu-bio Nederland  
Leids Universiteits Fonds 
BD Biosciences Nederland 
Voor mijn ouders 

Contents
Thesis outline         page 8 
Chapter 1:   14-3-3 proteins      page 11 
Chapter 2:   14-3-3 proteins and the p53 family    page 25 
Chapter 3:   Cellular functions of 14-3-3ǅ in apoptosis and cell  page 41 
adhesion emphasize its oncogenenic character    
Chapter 4: Isoform-specific differences in rapid nucleocytoplasmic  page 57 
shuttling cause distinct subcellular distributions of  
14-3-3ǅ and 14-3-3ı
Chapter 5: Radiation response and cell cycle regulation of p53  page 83  
rescued malignant keratinocytes 
Chapter 6: TwinGFP, a marker for cell cycle analysis in transiently page 109 
transfected cells 
Chapter 7: RT-PCR analysis of p73 splice variants, ease or tease? Page  121 
x Samenvatting voor de leek      page 127  
x Publications         page 133 
x Color figures         page 134 
x Conclusions and future directions     page 137 
x Curriculum vitae        page 139 
Thesis outline 
14-3-3 proteins constitute a family of highly homologous, conserved proteins, 
abundantly expressed in all eukaryotic organisms studied so far. There are seven 
human 14-3-3 isoforms (ǃ, Ǆ, İ, ǆ, ı, Ĳ and ǅ), all expressed from different genes. By 
their interaction with binding partners, 14-3-3 proteins regulate many cellular 
processes that are important to cell biology, such as signal transduction, 
transcriptional control, apoptosis, cell-cycle control, differentiation and stress 
response. The general properties of 14-3-3 proteins are discussed in chapter 1.
Because most of the studies presented in this thesis where performed in keratinocyte 
cells, the role of 14-3-3 proteins in these cells is described in more detail. 
In recent years more and more direct connections between 14-3-3 proteins 
and members of the p53 family of transcription factors have emerged in literature. 
The p53 family consists of three genes, p53, p63 and p73 which are involved in the 
same or similar cellular processes as 14-3-3 proteins. An introduction into the p53 
family and the direct relationships between this family and 14-3-3 proteins are 
discussed in chapter 2. Also in this chapter, the role of these proteins in 
keratinocytes is emphasized. 
Since human 14-3-3 proteins are highly homologous, have similar protein 
structures and biochemical properties, as discussed in chapter 1, the different 14-3-3 
isoforms are often assumed to all behave in a similar way. Nervertheless, isoform-
specific 14-3-3 actions have been observed. In chapter 3, isoform specific functions 
in tumorigenesis of one of the 14-3-3 proteins, 14-3-3ǅ, were studied after specific 
downregulation of this isoform in an immortal human keratinocyte cell line. 
14-3-3 proteins are localized in the cytoplasm of a cell, but also in the nucleus 
albeit at a lower concentration. Differences in nucleocytoplasmic shuttling of 14-3-3 
proteins might reflect a molecular basis for isoform-specific biological specialisation. 
Therefore, the differences in subcellular distribution and dynamic localization 
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between 14-3-3ı and 14-3-3ǅ Оwere studied in varying living mammalian cells in 
chapter 4.
Indications accumulate that the 14-3-3ı isoform is unique among the 14-3-3 
proteins. In contrast to other 14-3-3 isoforms which are ubiquitously expressed, 14-
3-3ı is expressed only in epithelial cells and it has a crucial role in the differentiation 
of keratinocytes. In cell types other than keratinocytes several links between p53 
family members and especially the 14-3-3ı isoform have been found. In colorectal 
cancer cells 14-3-3ı is induced by p53 following irradiation, which is required for 
proper G2 arrest. In chapter 5, the possible involvement of 14-3-3ı transactivation 
or stabilization in radiation induced G2 arrest in keratinocytes in a p53 regulated 
keratinocyte cell line is studied. In chapter 6 the retention of a double GFP protein 
is monitored in p53 transfected and permeabilized keratinocyte cells. Finally, in 
chapter 7, a widely used method to detect different p73 splice variants is critically 
assessed.
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14-3-3 proteins 
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Introduction
14-3-3 proteins are a family of highly conserved, acidic proteins with a size of 
approximately 30 kD, abundantly expressed in a wide range of organisms and 
tissues. The unusual name was given during a systematic attempt to classify bovine 
brain proteins. The 14-3-3 proteins eluted in the 14th fraction of bovine brain extract 
and were found on positions 3.3 of subsequent starch-gel electrophoresis by Moore 
and Perez (Moore & Perez, 1967). All eukaryotic organisms express multiple 14-3-3 
isoforms, ranging from 2 in yeast and 7 in mammalian cells up to 15 in plants. 
Despite this genetic diversity, 14-3-3 proteins display an amazing level of sequence 
conservation between isoforms. For example, the 14-3-3 isoform BMH1 from 
Saccharomyces cerevisiae (yeast) is, at the amino acid level, approximately 70% 
similar compared to the human 14-3-3İ isoform (Wang & Shakes, 1996). 
Mammalian 14-3-3 isoforms were initially named Į, ǃ, Ǆ, į, İ, ǆ and ǅ after the 
reversed phase HPLC separation pattern of 14-3-3 proteins isolated from bovine 
brain (Ichimura et al., 1988). However, Aitken et al. showed that the Į and į forms 
identified by Ichimura et al. represent the phosphorylated forms of ǃ and ǅ
respectively (Aitken, 1995). The 14-3-3Ĳ isoform (sometimes called Ǉ) was originally 
identified as a T-cell specific isoform (Nielsen, 1991), but it was shown that other cell 
types also express this variant (Aitken, 2006). The last mammalian isoform 
discovered was the ı isoform (also called stratifin or HME1), which is expressed only 
in epithelial cells (Leffers et al., 1993; Prasad et al., 1992). So, in total, mammalian 
(including human) cells express 7 different 14-3-3 isoforms called ǃ(Į), Ǆ, İ, ǆ, ı,
Ĳ(Ǉ) and ǅ(į).
The high degree of sequence conservation and the abundance of 14-3-3 
proteins in all eukaryotic organisms studied until now, suggest that they are of 
fundamental biological importance for organisms ranging from yeast to humans. 
More than 20 years after the discovery of 14-3-3 proteins, were they were identified 
simply as abundant brain proteins with unknown function, the first experimental 
evidence that 14-3-3 proteins play an important role in cell biology emerged when 
they were found to interact with proto-oncogene and signalling proteins (Aitken et 
al., 1990; Reuther et al., 1994; Toker et al., 1990). 
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Over 300 14-3-3 interacting proteins have been identified until now (Aitken, 
2002; Fu et al., 2000; Pozuelo Rubio et al., 2004; van Hemert et al., 2001), however, 
for most binding partners it is still unclear whether binding is specific for one isoform 
or if it can be achieved by several or all 14-3-3 isoforms. Among the 14-3-3 binding 
partners are proteins involved in major cellular processes such as cell cycle control, 
intracellular signalling, stress response, apoptosis, transcriptional regulation, cellular 
metabolism, cytoskeletal integrity, cell motility, adhesion and differentiation. 
Accordingly, a prominent role for 14-3-3 proteins in these processes has been 
accentuated by experimental studies; these are reviewed in (Aitken, 2006; Aitken et 
al., 1995; Berg et al., 2003; Burbelo & Hall, 1995; Darling et al., 2005; Fu et al., 
2000; Hermeking, 2003; Hermeking & Benzinger, 2006; Lee & Lozano, 2006; Masters 
et al., 2002; Porter et al., 2006; Reuther & Pendergast, 1996; Rosenquist, 2003; 
Tzivion & Avruch, 2002; Tzivion et al., 2006; Tzivion et al., 2001). 
Structure, dimerization and binding 
Amino-acid sequence comparison of 14-3-3 proteins from various organisms 
shows that 14-3-3 proteins consists of five highly conserved blocks separated by less 
conserved regions and suggests that 14-3-3 proteins in all organisms share a very 
similar structure (Wang & Shakes, 1996). The first two human 14-3-3 X-ray crystal 
structures solved were those of the ǅ and the Ĳ isoforms (Liu et al., 1995; Xiao et al., 
1995). These studies revealed almost identical dimeric structures. Each 14-3-3 
monomer is composed of nine Į-helices (referred to as ĮA-ĮI) organised in an 
antiparallel fashion, creating an L-shaped structure (see figure 1). The four N-
terminal helices mediate dimerization and form a planar surface to which the five C-
teminal helices have a rectangular orientation, creating a U-shaped (clamp-like) 
dimer. The crystal structures of all human 14-3-3 isoforms have now been solved; in 
general the structures are very similar, which is not surprising considering the high 
degree of sequence conservation (Gardino et al., 2006). Of the 7 human 14-3-3 
isoforms, the 14-3-3ı form shows the most deviant structure (Wilker et al., 2005). 
Accordingly, experimental data accumulate that 14-3-3ı shows much more isoform-
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specific activities than other 14-3-3 isoforms (Dellambra et al., 2000; Hermeking, 
2003; Hermeking & Benzinger, 2006; Lee & Lozano, 2006). 
Figure 1. Structure of a 14-3-3 (zeta) dimer, organization of the nine D-helices in the left monomer is 
indicated (A-I).
The dimer contact residues are highly conserved among human 14-3-3 
isoforms (Wang & Shakes, 1996), this allows some isoforms to form heterodimers as 
well as homodimers. The human 14-3-3İ variant even forms heterodimers 
preferentially, while the ı and Ǆ variants normally only form homodimers (Benzinger 
et al., 2005; Chaudhri et al., 2003; Gardino et al., 2006; Wilker et al., 2005).  The 
difference in propensity to homo- or heterodimerize is thought to be determined by 
difference in salt-bridges between the 14-3-3 isoforms (Gardino et al., 2006). The 
crystal structure of 14-3-3ı revealed that the ı isoform contains a unique salt bridge, 
alternative to the salt bridges in the other isoforms, this likely accounts for the 
homodimeric character of this isoform (Wilker et al., 2005). 
A combination of mutational analysis and co-crystallization studies of 14-3-3 
proteins with binding peptides showed that a target binding groove is formed in the 
14-3-3 dimer, composed of residues from both N-terminal and C-terminal regions of 
14-3-3 proteins (Ichimura et al., 1995; Liu et al., 1995; Wang et al., 1998; Xiao et 
al., 1995). The C-terminal Į-helices form the walls of the U-shaped 14-3-3 dimer, 
creating the binding groove between the two L-shaped monomers. The interior of 
each monomer consists of two Į-helices with charged and polar amino acids (ĮC and 
ĮE) and two with hydrophobic amino acids (ĮG and ĮI), forming a highly conserved 
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concave amphipathic groove that acts as a binding channel, binding specific motifs in 
the target protein (Petosa et al., 1998; Wang et al., 1998).  Therefore, each 
monomer is capable of binding a specific motif in a target protein, allowing a 14-3-3 
dimer to bind two motifs simultaneously, this can be either two motifs in the same 
target protein or binding two target proteins, one motif each (Liu et al., 1995; Obsil 
et al., 2001; Rittinger et al., 1999; Xiao et al., 1995; Yaffe et al., 1997). See figure 2 
for a schematic representation of a 14-3-3 dimer.
 Figure 2. Schematic representation of a 14-3-3 dimer. 14-3-3 monomers are shown in black 
(monomer 1) and grey (monomer 2). 
14-3-3 target binding is usually regulated by phosphorylation of a potential 
14-3-3 binding motif in the target protein. The early findings that 14-3-3 target 
proteins tryptophan and tyrosine hydroxylase (Furukawa et al., 1993; Ichimura et al., 
1988) and Raf and Bcr (Michaud et al., 1995) required phosphorylation for 14-3-3 
binding stimulated a more specified study to determine the specific requirements for 
14-3-3 binding (Muslin et al., 1996). In this study, Muslin et al. identified a 14-3-3 
binding motif consisting of RSxpSxP, where pS represents phophoserine and x any 
amino acid. Later, using phosphopeptide libraries, evidence was provided that there 
are two distinct 14-3-3 binding motifs, RSxpSxP (mode 1) and RxĳxpSxP (mode 2) 
where pS represents either phosphoserine or phosphothreonine, ĳ an aromatic or 
aliphatic amino acid and x any amino acid (Rittinger et al., 1999; Yaffe et al., 1997). 
In addition to these well-defined motifs recognized by all 14-3-3 isoforms, 14-3-3 
proteins are capable of binding variations of the modes 1 and 2 motifs (Tzivion et al., 
2001) and other less well characterized phosphorylated motifs in target proteins 
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might also be recognized by 14-3-3 proteins (Coblitz et al., 2006). Most interactions 
between 14-3-3 proteins and binding partners depend on phosphorylation of the 
target, however, several interactions have also been described that do not require 
phosphorylation at all, these are summarized in (Gardino et al., 2006).
Modes of action 
Although for most 14-3-3 binding partners the function of 14-3-3 binding is 
not clear yet, some general mechanisms by which 14-3-3 association regulates the 
function of its targets have emerged (Hermeking, 2003; Tzivion & Avruch, 2002; 
Tzivion et al., 2001; van Hemert et al., 2001). A single 14-3-3 binding partner can be 
regulated by only one or by a combination of these mechanisms. The mechanisms 
can be arranged into five general modes of action (see figure 3): 
1) 14-3-3 binding can alter the subcellular localization of the target protein 
and sequester it (normally) in the cytoplasm. This is the most commonly described 
mode of action for 14-3-3 proteins. There are two mechanisms by which this may be 
accomplished: First, 14-3-3 proteins can facilitate the re-localization of the target 
protein from the nucleus to the cytoplasm via a nuclear export sequence in the 14-3-
3 protein, and second, binding of 14-3-3 may cover up a nuclear import sequence in 
the target protein and reduce the nuclear import rate. Both mechanisms result in the 
sequestration of the target protein in the cytoplasm. Proteins regulated in this 
manner include: Cdc25C (Dalal et al., 1999; Kumagai & Dunphy, 1999), 
Cdc2/cyclinB1 complex (Chan et al., 1999), p27 (Fujita et al., 2002) and   FKHRL1 
(Brunet et al., 1999). 
2) 14-3-3 binding can prevent the interaction of the target protein with other 
proteins. For example, 14-3-3 binding to the pro-apoptotic protein BAD prevents 
binding to the anti-apoptotic protein Bcl2 (Datta et al., 2000; Hsu et al., 1997; Zha et 
al., 1996). In this case, the result of 14-3-3 association is inhibition of apoptosis 
because 14-3-3 binding to Bad relieves the Bcl2 protein, which is then free to 
perform its survival promoting function. Another example of this mode of action is 
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14-3-3 binding to IRS-I, which prevents activation of PI-3K by IRS-I (Kosaki et al., 
1998).
3) 14-3-3 proteins can act as a scaffold to bridge two targets. 14-3-3 proteins 
can bind two targets at the same time and stimulate their interaction. This mode of 
action has been described for the interactions of Raf with Bcr (Braselmann & 
McCormick, 1995), A20 (Vincenz & Dixit, 1996) and PKC (Van Der Hoeven et al., 
2000).
Figure  3. 14-3-3 modes of action. See text for details.   
4) Binding of 14-3-3 proteins can alter the activity of the target protein and 
inhibit or enhance its activity. A few examples are: 14-3-3 association enhances 
tryptophan and tyrosine hydroxylase activities (Ichimura et al., 1988) and p53 DNA 
binding capacity (Waterman et al., 1998) and 14-3-3 association inhibits ASK-I 
activity (Liu et al., 2001; Zhang et al., 1999) and RGS activity (Benzing et al., 2000).  
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5) 14-3-3 binding can protect a target protein from modifications such as 
dephosphorylation and modifications signalling for proteolysis.  14-3-3 binding to Raf
(Dent et al., 1995; Thorson et al., 1998), histones (Chen & Wagner, 1994) and BAD 
(Chiang et al., 2001) prevents dephosphorylation of the targets. Association of 14-3-
3 with p53 (Yang et al., 2003), plant nitrate reductase (Weiner & Kaiser, 1999) and 
other 14-3-3 targets in Arabidopsis (Cotelle et al., 2000) protects the partners from 
proteolysis.
14-3-3 proteins and keratinocytes 
 The outermost layer of the human skin is the epidermis, which is mainly 
composed of keratinocyte cells. Early 14-3-3 research indicated that 14-3-3 proteins 
might have a specific role in keratinocytes. They are capable of enhancing protein 
kinase C (PKC) activity, which is involved in the regulation of keratinocyte 
differentiation (Dellambra et al., 1995). Keratinocytes form a stratified epithelium 
consisting of several distinct layers, named basal layer, spinous layer, granular layer 
and the cornified layer (Fuchs & Raghavan, 2002). They are constantly renewed 
through division of stem cells in the basal layer, they move upwards towards the 
outside edge of the skin as they (terminally) differentiate and give rise to the various 
layers of the epidermis, resulting in lifeless flattened squames forming the cornified 
layer, which ultimately detach from the skin (Alonso & Fuchs, 2003; Roop, 1995).  
Each layer is characterized by a specific protein profile of differentiation markers such 
as keratins, involucrin, loricrin, fillaggrin and sprr proteins, classifying the state of 
differentiation (Alonso & Fuchs, 2003; Cabral et al., 2001; Fuchs & Green, 1980; 
Fuchs & Raghavan, 2002; Roop, 1995). Keratins are major structural proteins, they 
form a family of approximately 30 members expressed in a differentiation specific 
manner in epithelial cells (Fuchs & Green, 1980; Steinert & Roop, 1988). Defects in 
keratin functioning can result in various skin defects which are typical for the 
epidermal layer expressing the malfunctioning keratin (Roop, 1995). 
 Different keratins have been identified as 14-3-3 binding partners by several 
independent groups (Kim et al., 2006; Ku et al., 2002; Liao & Omary, 1996; Omary & 
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Ku, 2006; Pozuelo Rubio et al., 2004). It is not entirely clear which 14-3-3 isoforms 
bind which keratins and how isoform specific this binding is and for most interactions 
the function of 14-3-3 binding remains to be elucidated. Kim et. al  showed that the 
interaction between keratin 17 and 14-3-3ı likely plays an important role in 
epidermal wound healing (Kim et al., 2006).  However, the isoform-specificity has to 
be clarified since other (yeast) 14-3-3 proteins have also been shown to bind human 
keratin 17 (Pozuelo Rubio et al., 2004).
 14-3-3ı expression is restricted to epithelial cells (Leffers et al., 1993), which 
suggest an isoform specific role in these types of cells, it was suggested that this role 
might be differentiation of epithelial cells. Dellambra et al. showed that 14-3-3ı Оis
expressed at relatively low levels in basal keratinocyte cells, at high levels at the 
moment of commitment to terminal differentiation and again at low levels when 
differentiation is completed (figure 4). 14-3-3ı is absolutely required for 
differentiation of human epidermal keratinocytes since downregulation of 14-3-3ı
prevents differentiation of primary human keratinocytes by forcing them into the 
stem cell compartment, this allows the cells to escape from replicative senescence 
and become immortal (Dellambra et al., 2000).
Figure 4. Expression of 14-3-3ı in human skin. Human skin was stained with a 14-3-3ı-specific 
antibody. 14-3-3ı is barely detectable in the basal layer (arrows), increasingly expressed in 
suprabasal layers (arrowheads) and undetectable in the cornified layer (asterisks). Picture adapted 
from (Dellambra et al., 2000). 
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A fine balance between extracellular matrix (ECM) synthesis and degradation 
is of crucial importance for the maintenance of the skin’s structural integrity and for 
repair of injured skin. Excessive wound healing is characterized by increased 
deposition of ECM which often results in fibrotic conditions. Differentiated 
keratinocytes excrete 14-3-3ı; this stimulates expression of extracellular matrix 
degrading proteins such as MMP-1, MMP3 and collagenase-1 (and others) by dermal 
fibroblasts. Excreted 14-3-3ı also downregulates expression of structural ECM 
proteins in fibroblasts, together this indicates that 14-3-3ı excreted by keratinocytes 
plays a major role in structuring the skin and preventing fibrotic conditions after skin 
injury (Ghaffari et al., 2006; Ghahary et al., 2004).
Taken together, 14-3-3 proteins have clearly been shown to be involved in 
keratinocyte physiology. Especially the 14-3-3ı isoform has a crucial role in 
kerationcyte differentiation and maintenance of skin structure.
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Introduction
14-3-3 proteins are involved in many cellular processes, including processes 
regulated by the p53 family of transcription factors. Indirect links comprise 14-3-3 
proteins associating with various transcriptional targets of p53 family members 
(Benzinger et al., 2005; Fu et al., 2000; Pozuelo Rubio et al., 2004; van Hemert et 
al., 2001). However, more direct connections have also been observed, these will be 
discussed in this chapter. The direct relationship between 14-3-3 proteins and 
members of the p53 family mainly focuses on 14-3-3ı because all p53 family 
members are capable of transactivating this isoform. However, multiple 14-3-3 
isoforms can bind p53 family members and regulate their activity. So, p53 family 
members directly regulate 14-3-3 and vice versa 14-3-3 isoforms directly regulate 
p53 family members.
The p53 family 
The p53 family was named after p53, the first family member, discovered in 
1979 (DeLeo et al., 1979). The p53 gene encodes a sequence specific transcription 
factor, activated in response to stress signals such as radiation and other types of 
genotoxic damage. Increased levels of p53 prevent replication of damaged cells by 
enhancing the expression of genes inducing cell-cycle arrest and programmed cell 
death (apoptosis). P53 has become one of the most intensively studied genes in 
cancer biology, it was found that the gene is mutated or inactivated in over 50% of 
all human cancers and p53 is now considered the most important tumor-suppressor 
in mammals (Bates & Vousden, 1996; Horn & Vousden, 2004; Lane, 1994; Morgan & 
Kastan, 1997; Prives & Hall, 1999; Steele et al., 1998; Vogelstein et al., 2000). The 
role as tumor-suppressor is accentuated by p53-null mouse models, which show that 
mice lacking p53 spontaneously develop various types of tumors and die of cancer 
two to twelve months after birth (Donehower et al., 1992; Jacks et al., 1994).
Considering the importance of p53 in cancer research perhaps surprisingly, the 
two p53 homologues p63 and p73 were discovered 20 years after the discovery of
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p53. P73 was identified in 1997 (Kaghad et al., 1997) and later several 
research groups independently identified p63 (Osada et al., 1998; Schmale & 
Bamberger, 1997; Senoo et al., 1998; Tan et al., 2001; Trink et al., 1998; Yang et 
al., 1998), which resulted in several alternative names for p63 (KET, p40, p73L, 
p53CP and NBP).  The three p53 family members are very homologous and all three 
contain a conserved transactivation domain (TA), a DNA binding domain (DBD) and 
an oligomerization domain (OD) (also called tetramerization domain) (Yang & 
McKeon, 2000). The highest sequence similarity is found in the DNA binding domain, 
where almost all tumor related mutations in p53 are found, this region is over 60% 
identical in all three family members. In experimental systems, p63 and p73 showed 
behaviour mimicking p53, such as binding p53 target sites, transactivating p53 target 
genes and inducing p53-like phenotypes (Ishida et al., 2000; Jost et al., 1997; Osada 
et al., 1998; Shimada et al., 1999; Yang et al., 1998; Zhu et al., 1998). However, 
despite the sequence conservation and the similarities in behaviour in experimental 
systems, the functions of p63 and p73 appear to differ from those of p53 in vivo.  In 
contrast to p53 null-mice, severe developmental abnormalities are observed in p63 
and p73 null mice (figure 1). P73 null mice are much smaller than p53 null or wild-
type mice and show neurological, pheromonal and inflammatory defects but they 
lack spontaneous tumors (Yang et al., 2000).  P63 null-mice show severe defects in 
limb and epithelial development. Because the skin of these mice is not developed 
properly (explained in more detail below), they die from dehydration soon after birth 
which eliminates the possibility of investigating the tumor-suppressing capacity of 
p63 in this system (Mills et al., 1999; Yang et al., 1999). 
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Figure 1. P63 and p73 deficient mice show severe developmental abnormalities. (a) p63 -/- mice on 
postnatal day 1 show severe skin and limb defects. (b) p73 -/- mice at postnatal day 10 are 
significantly smaller than p73 +/+ and p73 +/- mice. Pictures were adapted from Yang et al., 1999 
(a) and Yang et al., 2000 (b). 
Until 2005, p53 expression was usually regarded as simple; a single promoter 
directs the synthesis of one protein which transactivates a specific set of target 
genes. The p63 and p73 genes were found to be much more complex, giving raise to 
proteins that either resemble p53 function but also proteins that counteract the 
function of p53. P63 and p73 are both expressed from two independent promoters 
and present a variety of alternative splice-variants, which results in a complex array 
of p63 and p73 proteins (Yang & McKeon, 2000). See figure 2 for a schematic 
representation of the p53 family members.
Transcription of both p63 and p73 can start from either exon 1 or from an 
additional exon 3’ (located between exon 3 and 4). P63 or p73 proteins expressed 
from exon 3’ lack the N-terminal part of the protein which houses the transactivation 
domain, these proteins are usually incapable of transactivation. In fact, these forms, 
named ƩN variants, normally act as dominant negatives for p63, p73 and p53 
proteins that do contain a transactivation domain (TA forms) and counteract their 
function (De Laurenzi & Melino, 2000; Irwin & Kaelin, 2001; Levrero et al., 2000; 
Marin & Kaelin, 2000; Yang et al., 2002; Yang & McKeon, 2000). In addition to the 
ƩN forms, other variations in the N-terminal regions have also been found, reviewed 
in (Moll & Slade, 2004).
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 P53 family members assemble into tetramers (by means of the 
oligomerization domain) to form an active complex. Because the oligomerization 
domains are conserved in all p53 family members, formation of heterotetramers is 
possible, although homo-tetramerization is favoured (Davison et al., 1999; De 
Laurenzi & Melino, 2000). Tetramers built up solely from ƩN isoforms compete for 
specific DNA sites in the promoter regions of target genes and prevent DNA binding 
and thus transactivation by (active) p53, TAp63 or TAp73 tetramers. In addition, 
because all ƩN p63 and p73 forms still contain the oligomerization domain, they can 
be incorporated into a tetrameric complex containing TA forms, which inactivates the 
tetramer (Grob et al., 2001; Marin & Kaelin, 2000; Yang & McKeon, 2000).  Although 
ƩN p63 or p73 show repressor activity in almost all experiments, there are 
exceptions that indicate that some ƩN forms might sometimes have a positive role in 
transactivation (Liu et al., 2004).
In addition to alternative use of promoters, p63 and p73 also give rise to a 
variety of C-terminal splice variants. The full-length C-terminal splice-variants, 
designated p63Į and p73Į both contain a sterile (sometimes called steric) Į-motif 
(SAM domain) and a transcription inhibitory domain (TID) in addition to the 
transactivation domain, the DNA binding domain and the oligomerization domain also 
present in p53 (De Laurenzi & Melino, 2000; Yang et al., 2002; Yang & McKeon, 
2000). P63 expresses three C-terminal splice variants, Į, ǃ and Ǆ. The p63 gene 
consists of 15 exons, compared to the full-length Į variant, the ǃ form lacks exon 13 
which is part of the SAM domain. P63Ǆ lacks exons 11 to 14, containing the complete 
SAM domain and the TID domain. Both the SAM and TID domains usually inhibit 
transactivation of p63 target genes although the effect of these domains varies 
between targets. Because regions that are not found in p53 are spliced out in p63ǃ
and Ǆ, these isotypes structurally resemble p53 more than p63Į. In contrast to p63Į,
experimental evidence shows that TAp63ǃ and TAp63Ǆ transactivate p53 inducible 
genes at levels similar to p53 and ectopically expressed TAp63ǃ and TAp63Ǆ induce 
apoptosis or cell cycle arrest, similar to p53 (Osada et al., 1998; Yang et al., 1998).
P73 splicing is similar to p63 but even more complex, at least eight p73 
proteins alternative to the full-length Į form are generated by splicing of the C-
terminus, named ǃ, Ǆ, į, İ, ĳ, ǅ , ǆ and ǆ1 (De Laurenzi & Melino, 2000; Ishimoto et 
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al., 2002; Kaghad et al., 1997; Moll & Slade, 2004; Stiewe et al., 2002; Yang et al., 
2000). The most important splice-variants are schematically shown in figure 2. Like 
p63, TAp73 splice-variants structurally resembling p53 more than p73Į generally 
show more p53-like characteristics.     
Figure 2. Schematic representation of p53 family structure. The main structural domains, 
transactivation domain (TA), DNA binding domain (DBD), oligomerization domain (OD), sterile 
alpha motif (SAM) and the transcription inhibitory domain (TID) are indicated below the structures. 
Arrows represent promoter start sites. Splicing is indicated by dotted lines, only the most important 
splice variants are indicated. 
The identification of C-terminal splice variants and use of alternative 
promoters for p63 and p73 stimulated the search for alternative p53 variants. 
Indeed, the more sophisticated techniques currently available allowed the 
identification of p53 variants other than the commonly described p53 protein and 
also for p53, C-terminal splice variants and use of alternative promoters has been 
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detected (Bourdon et al., 2005). The human p53 gene encodes at least nine 
different p53 isoforms named p53, p53ǃ, p53Ǆ, Ʃ133p53, Ʃ133p53ǃ, Ʃ133p53Ǆ,
Ʃ40p53, Ʃ40p53ǃ and Ʃ40p53Ǆ (figure 2), they are expressed in normal human 
tissues, in a tissue-dependent manner. Early experiments indicate that p53 
variants show activities comparable to corresponding p63 or p73 variants. For 
example, p53ǃ binds differentially to promoters and enhances expression of p53 
target genes in a promoter-dependent manner and Ʃ133p53 shows dominant-
negative capacities towards (normal) p53. Considering the biological importance of 
ƩN and C-terminal p63 and p73 variants, it is likely that the novel p53 variants 
exhibit very important biological functions. However, because these novel p53 
variants were discovered only recently and information about their functions is 
exceptionally limited, these variants will not be dicussed further and when p53 is 
mentioned it indicates full-length p53. 
From accumulating experimental data, it is becoming clear that p63 and p73 
show important functional differences to each other and to p53. Whereas p53 
remains the principle tumor suppressor in mammalian cells, gene specific roles for 
p63 include epithelial cell maintenance, development of skin, limbs, breast 
urothelium and prostate. Specific roles for p73 include neuron survival, 
hippocampal neurogenesis, cerebral fluid homeostasis, reviewed in Yang et al., 
2002. However, there is no doubt that p53 family members also have similar 
biological functions. In fact, p63 and p73 appear to be essential for p53 
functioning in response to DNA damage because the family members enhance the 
binding of p53 to target gene promoters (Flores et al., 2002).  Also, genes have 
been found that can be transactivated by (splice-variants of) all three family 
members, these include p21, bax, mdm2, cyclin-G, gadd45, IGFBP (De Laurenzi et 
al., 1998; Jost et al., 1997; Kaghad et al., 1997; Osada et al., 1998; Yang et al., 
1998; Zhu et al., 1998). All p53 family members are also capable of 
transactivating 14-3-3ı; this will be discussed in more detail in the next 
paragraph.
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Serial analysis of gene expression (SAGE) showed that 14-3-3ı is upregulated 
after DNA-damage induction in colorectal cancer cell lines expressing wild-type p53. 
It was also shown that 14-3-3ı is not upregulated following DNA damage in 
colorectal cancer cells expressing mutant p53, suggesting that p53 is directly 
involved in the transactivation of 14-3-3ı. Ectopically overexpressed wild-type p53 is 
capable of increasing 14-3-3ı mRNA levels without DNA damage in the same cell 
type. The p53 mediated induction of 14-3-3ı is required for maintaining a stable cell 
cycle arrest in G2 phase after DNA damage. Exogenous expression of 14-3-3ı results 
in G2 arrest in colorectal cells directly (Hermeking et al., 1997). Cells deficient for 14-
3-3ı fail to sequester the cdc2/cylinB1 complex and die of mitotic catastrophe in 
response to DNA damage (Chan et al., 1999). Transactivation of 14-3-3ı by p53 is 
mediated through a functional p53-binding site, located in the promoter region of the 
14-3-3ı gene, 1.8 kilobases upstream of the 14-3-3ı transcription start site 
(Hermeking et al., 1997).
The same motif binds ƩNp63Į, however as expected from the lack of a 
transactivation domain, this protein represses transcription of 14-3-3ı (Westfall et 
al., 2003). Because ƩNp63Į protein is capable of binding the p53-binding sites in the 
14-3-3ı promoter and TAp63 splice-variants contain exactly the same DNA binding 
domain it is likely that the latter forms are capable of transactivating 14-3-3ı.
Experimental support for this came from the finding that in p53-negative 
hepatocytes, both TAp63 and 14-3-3ı are induced following DNA damage, 
suggesting that in this case TAp63 is responsible for 14-3-3ı transactivation 
(Fomenkov et al., 2004).
TAp73 forms also transactivate the 14-3-3ı gene, when ectopically expressed, 
the TAp73Į and ǃ variants even showed 3 to 6 times higher transactivation of 14-3-
3ı than p53 itself (Zhu et al., 1998). In contrast to what is regarded the normal 
function of ƩN splice variants, also ƩNp73ǃ and ƩNp73Ǆ are capable of inducing 14-
3-3ı, in fact, in MCF-7 cells, ƩNp73ǃ was more active in inducing 14-3-3ı than the 
TA form of p73ǃ (Liu et al., 2004). The authors of this paper suggest that the ƩNp73 
variants form an alternative activation domain in the unique N-terminal residues of 
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the protein, which is responsible for the transactivation of some of the p53 target 
genes. 14-3-3ı appears to be exceptionally sensitive for activation by this domain 
since it was the only gene in this study that was induced more effectively by ƩNp73ǃ
than by TAp73ǃ (Liu et al., 2004). 
Figure 3. Direct relationships between 14-3-3 proteins and the p53 family. After DNA damage, p53 
family members bind a p53 binding-site (p53 BS) in the 14-3-3ı promoter. P53, TAp63, TAp73 and 
ƩNp73 variants transactivate 14-3-3ı which in return binds p53 itself, hereby stabilizing p53, 
increasing DNA binding and thus transcription by p53, creating a positive feedback loop. DNA damage 
creates a 14-3-3 binding-site in p53 where other 14-3-3 isoforms can bind p53, which enhances 
transactivation by increasing the DNA binding capacity of p53.  Binding of ƩNp63 to the p53 binding-
site inhibits transactivation of 14-3-3ı and association of ƩNp63 with 14-3-3ı results in degradation of 
ƩNp63. See text for details.
P53 is constitutively phosphorylated at serines 376 and 378 and after DNA 
damage induced by Ǆ-irradiation, p53 is dephosphorylated at serine 376, which 
creates a 14-3-3 binding-site centred by serine 378. This motif can bind 14-3-3Ǆ, 14-
3-3Ĳ and 14-3-3İ, which enhances p53 function by increasing sequence specific 
binding to DNA, resulting in higher transactivation potential (Stavridi et al., 2001; 
Waterman et al., 1998).
P53 stability is regulated by MDM2, which is a ubiquitin ligase that decreases 
the half-life of p53 by marking p53 with ubiquitin leading to degradation by the 
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ubiquitin-proteasome pathway (Iwakuma & Lozano, 2003). 14-3-3ı itself binds p53 
in response to DNA damage; this binding has a positive effect on p53 stability and 
increases its half-life by preventing degradation mediated by MDM2. Increased levels 
of 14-3-3ı also lead to destabilization of MDM2 itself. In addition, 14-3-3ı binding to 
p53 promotes tetramerization, resulting in increased transcriptional activity, similar to 
binding of 14-3-3Ǆ, 14-3-3Ĳ and 14-3-3İ to p53 (Yang et al., 2003). So, following 
DNA-damage, 14-3-3ı modulates the activity of p53, which can in turn result in 
transactivation of 14-3-3ı itself, thus creating a positive-feedback loop. The opposite 
appears to be true for ƩNp63Į, because it lacks a transactivation domain, this 
protein inhibits transactivation of 14-3-3ı, in response to DNA damage 14-3-3ı binds 
to ƩNp63Į and transports it from the nucleus to the cytoplasm of the cell where it is 
ubiquitinated and degraded (Fomenkov et al., 2004).
A schematic representation of the information reviewed in this paragraph (14-
3-3 proteins and the p53 family) is shown in figure 3. It must be noted however that 
the actions described might be cell-type specific or limited to one or a few specific 
splice variants. Conversely, possibly actions have only been described for one or a 
few p53 family members or 14-3-3 isoforms while other family members behave in 
the same or similar way.
P53 family and keratinocytes 
The p53 family is undoubtedly involved in the regulation of epidermal 
keratinocytes and p63 is clearly the most important family member of the three. P63 
is absolutely essential for keratinocyte differentiation, as mentioned before, mice 
lacking p63 are completely unable to form stratified epithelia including epidermis 
(figure 4).  
Figure 4. Defects in epidermal differentiation in p63-deficient mice. P63 -/- mice lacking squamous 
stratification in the epidermis. Picture adapted from Yang et al., 1999.
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Keratinocytes arise from epidermal stem cells, which give rise to daughter 
stem cells and transit amplifying cells through asymmetric cell division. Transit 
amplifying cells withdraw from the cell-cycle after a few rounds of division and then 
undergo terminal differentiation (Roop, 1995). At embryonic day 9.5, when the 
epidermis is still single-layered, commitment to differentiation (stratification) is 
marked by the expression of keratins 5 and 14 (Byrne et al., 1994). P63 expression 
can be detected one day before the onset of keratin 14 expression, at embryonic day 
8.5, and it is now believed to be the master molecular switch for the induction of 
stratification (Yang et al., 1998; Koster et al., 2002). TAp63 isoforms are expressed 
just prior to stratification and ƩNp63 isoforms are the first forms detected after cells 
have committed to stratification, but before the onset of terminal differentiation 
(Koster et al., 2004). In mature epidermis, the predominantly expressed p63 form is 
ƩNp63Į (although other forms are also expressed), which is expressed mainly in the 
basal layer, whereas all p63 forms are downregulated in the differentiated layers 
(Yang et al., 1998; Koster et al, 2002; Parsa et al., 1999). The decrease of ƩNp63Į
during epidermal differentiation may be required to prevent binding of ƩNp63Į to the 
14-3-3ı promoter and inhibit its expression. Downregulation would allow expression 
of 14-3-3ı, which (as previously described in chapter 1) is essential for terminal 
differentiation of keratinocytes (Koster et al., 2004; Dellambra et al., 2000).
 The roles for the other two p53 family-members in keratinocytes are less 
obvious, mouse knock-out models for p73 (Yang et al., 2000) and p53 (Donehower 
et al., 1992; Jacks et al., 1994) show no obvious epidermal defects as observed in 
p63-deficient mice. Nevertheless, indications have been found that p53 and p73 are 
also involved in keratinocyte differentiation. One clear indication that p73 is involved 
in keratinocyte differentiation is that p73Ǆ and į induce expression of loricrin and 
involucrin, two markers of epidermal differentiation (De Laurenzi & Melino., 2000). 
P53 has been implicated in differentiation of keratinocytes because levels of p53 
protein decrease during epidermal cell differentiation. The differentiation specific 
decrease of p53 was accompanied with an elevated transcriptional activity of p53 
(Weinberg et al., 1995). Also, p53 overexpression in normal keratinocytes induced 
expression of the terminal differentiation marker involucrin (Woodworth et al., 1993) 
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and ectopic expression of p53 into skin cancer cells enhanced expression of proteins 
required for keratinization (brenner, 1993).  In retrospective, however, one should 
be careful with interpretations like these, as results were obtained at a time when 
the existence of the related p63 and p73 genes was not yet suspected. However, 
also after the discovery of p63 and p73, p53 has also been shown to contribute to 
keratinocyte differentiation as p53 rescued HaCaT cells (non-tumor immortal human 
keratinocytes) differentiate faster than the parental or control cells (Paramio et al., 
2000).
P53 and p73 variants might be involved in regulation of keratinocyte cell fate 
by regulating the expression of p63 regulated genes. As described previously, p53, 
p63 and p73 proteins have common targets and therefore targets involved in 
differentiation transactivated by p63 might be transactivated by p53 or p73 variants 
as well. Similarly, p53 and p73 variants increase transcription of p63 targets by co-
operating with p63 (Flores et al., 2002). 
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Abstract
14-3-3 proteins are relevant to cancer biology as they are key regulators of 
major cellular processes such as proliferation, differentiation, senescence and 
apoptosis. So far, the sigma isoform (14-3-3ı) has most directly been implicated in 
carcinogenesis and was recognised as a tumour-suppressor gene. The other six 
members of the mammalian 14-3-3 gene family likely behave as oncogenes, 
although direct evidence supporting this view is largely circumstantial. In this report 
we show that knockdown of 14-3-3ǅ induces at least two isoform-specific phenotypes 
that are consistent with a potential oncogenic activity during tumorigenesis. First, 
downregulation of 14-3-3ǅ sensitised cells to stress induced apoptosis and JNK/p38 
signalling and second, it enforced cell-cell contacts and expression of adhesion 
proteins. Apparently, the zeta isoform restrains both cell adhesion and the cellular 
propensity for apoptosis, two activities that are also restrained during carcinogenesis. 
The assumption that 14-3-3ǅ has oncogenic properties was substantiated with a web-
based meta-analysis (Oncomine), revealing that 14-3-3ǅ is overexpressed in various 
types of carcinomas. As the highly-conserved human 14-3-3 gene family encodes 
proteins with either tumour promoting or tumour suppressing activities, we infer that 
the cellular balance between the various 14-3-3 isoforms is crucial for the proper 
functioning of cells.
Running title: Oncogenic properties of 14-3-3ǅ
Key words: 14-3-3 zeta isoform; siRNA; UV irradiation; c-Jun N-terminal kinase; p38-
MAPK;E-cadherin;Oncomine.
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Main text 
Of the 7 highly homologous members of the human 14-3-3 gene family, the 14-
3-3ı isoform has directly been linked to human cancer. 14-3-3ı is the only family 
member transactivated by the p53 tumour suppressor in response to DNA damage 
and as such essential for controlling cell cycle progression in G2/M (Hermeking et al., 
1997). Moreover, epigenetic silencing of 14-3-3V has been found at high frequency 
in epithelial cancers, indicating that loss of 14-3-3ı expression is crucial to tumour 
development (Hermeking, 2003). Evidence for a direct role of the other six 14-3-3 
isoforms in tumorigenesis is largely circumstantial; intuitively these isoforms are likely 
to function as potential oncogenes, but activities have also been described that 
suggest a tumour-suppressing function (Tzivion et al., 2006).      
 To investigate whether 14-3-3 family members other than sigma have 
isoform-specific functions relevant for tumorigenesis, we created human HaCaT cell 
lines stably expressing small interfering RNA (siRNA) targeted specifically to the 14-
3-3ǅ isoform. Two independent clones, HZ3 and HZ4, showed very low 14-3-3ǅ
protein levels as compared to two control cell lines HP2 and HP3 (Fig. 1a). No 
difference was observed with an antibody detecting all human 14-3-3 isoforms, 
indicating that downregulation of 14-3-3ǅ does not significantly influence total cellular 
14-3-3 protein levels. Also, the expression of the 14-3-3ı isoform was similar in all 
cell lines (Fig. 1a). 14-3-3 expression levels were further investigated by quantitative 
RT-PCR (Fig. 1b). As expected, the HZ3 and HZ4 cell lines showed significantly lower 
14-3-3ǅ levels than HP2 and HP3 cell lines, whereas RNA levels of 14-3-3Ǉ, 14-3-3İ
and 14-3-3ǃ were similar in all four cell lines and 14-3-3Ǆ and 14-3-3ǆ RNA levels 
were hardly detectable (Fig.1b). These results demonstrate that the 14-3-3ǅ isoform 
was selectively downregulated in the HZ3 and HZ4 cell lines.      
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Figure 1. Specific cellular downregulation of 14-3-3ǅ. In all experiments human HaCaT cells were 
used. These stable cell lines are non-tumorigenic, form a normal differentiated epithelium when 
transplanted onto nude mice (Boukamp et al., 1988) and have been successfully used for studying 
early stages of  carcinogenesis (Burnworth et al., 2006). Cell lines expressing siRNA specific for 14-3-
3ǅ were created by using the target sequence 5’-ACAGCAGATGGCTCGAGAA cloned in pSuper as 
described (Brummelkamp et al., 2002). Individual puromycin-resistant transfectants were isolated 
after cotransfection with pPur18, a derivative of pRSV-H20 carrying the puromycin-N-acetyl-
transferase gene. a) 14-3-3ǅ downregulated cells HZ3 & HZ4 and control cells HP2 & HP3 were grown 
to 80% confluence in DMEM, 10% fetal bovine serum, 1 μg/ml puromycin at 37ºC and 5% CO2 and
lysed directly on the dishes. Protein extracts and Western blotting were as described 
(Niemantsverdriet et al., 2005). Blots were reacted with 14-3-3ǅ (C-16), 14-3-3ǃ (K-19) (detects total 
14-3-3), 14-3-3ı (N-14) specific antibodies (Santa Cruz Biotechnology) and detected with either 
donkey anti-Mouse- or anti-Goat-IgG-HRP and the ECL system (Amersham). b) HP2, HP3, HZ3 and 
HZ4 cells were grown to 80% confluence, RNA was isolated and reverse transcribed as described 
(Niemantsverdriet et al., 2005). Expression levels of 14-3-3ǅ, 14-3-3T, 14-3-3H, 14-3-3E, 14-3-3Ǆ and 
14-3-3K relative to GAPDH (internal control) were determined by Real-time RT-PCR analysis; *** 
indicates p-values < 0.001 in a two-tailed t-test; error bars represent standard error. (See 
supplementary methods for more details). 
While the spontaneous apoptosis rate was similar in all cell lines, UV-C radiation 
(10 J/m2) dramatically increased the apoptosis rate in 14-3-3ǅ downregulated cells (8 
fold difference with control cells, Fig. 2a). The increased sensitivity for apoptosis of 
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14-3-3ǅ downregulated cells was paralleled by a significantly higher UV induced 
activation of p38 (4 fold difference with HP cells) and JNK (2 fold difference) (Fig. 
2b). Both p38 and JNK are well known transducers of apoptotic signals (Dent et al., 
2003) and were shown to activate the pro-apoptotic protein Bax by inducing its 
translocation to mitochondria (Kim et al., 2006).
Figure 2. Downregulation of 14-3-3ǅ sensitises cells to UV induced apoptosis. HP2, HP3, HZ3 and 
HZ4 cells were grown to 80% confluence and either left unirradiated or irradiated with 10 J/m2 UV-C. 
Apoptotic cells were detected by Alexa488-labelled annexin V (Molecular Probes) combined with 
Hoechst 33258 (Sigma) DNA staining. Images of the same microscopic field were acquired with a 
Zeiss Axiovert 135 microscope using a phase contrast filter to detect all cells and a DAPI/GFP filter 
(Zeiss) to detect apoptotic cells. a) Graphic representation of the apoptosis percentage of HP2, HP3 
and 14-3-3] downregulated HZ3 and HZ4 cells, 24 hours after either mock-irradiation (dotted bars) or 
irradiation with 10 J/m2 UV-C (black bars). *** indicates p-values < 0.001 in a two-tailed t-test ; error 
bars represent standard error. b) Immunoblot analysis of untreated or irradiated (10 J/m2 UV-C) HP2, 
HP3, HZ3 and HZ4 cells with phosphospecific antibodies detecting respectively activated JNK (p-JNK) 
(lower band: JNK-1; upper band: JNK-2) and activated p38 (p-p38) (Cell Signalling Technology). Cell 
extracts were prepared 1 h after UV irradiation, and detection was as described in figure 1. Ponceau S 
staining of the blot confirms equal loading.  
This apoptotic pathway might actually be potentiated by release of 
phosphorylated BAD from 14-3-3ǅ sequestration, resulting in mitochondrial re-
localization and a concomitant neutralization of the anti-apoptotic function of Bcl-XL
(Hekman et al., 2006). No constitutive p38 or JNK phosphorylation was observed in 
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any of the 4 cell lines. It is also interesting to mention that the mitogenic ERK 
pathway (assessed following serum stimulation) was not affected by 14-3-3ǅ
downregulation (supplementary figure S1). Summarizing, our data demonstrate that 
in normal cells 14-3-3ǅ inhibits specifically stress induced p38 and JNK signalling and 
the triggering of the apoptotic response. Effective apoptosis is essential to prevent 
tumorigenesis in humans and evasion of apoptosis is considered one of the typical 
hallmarks of cancer cells (Hanahan and Weinberg, 2000).      
Figure 3. see next page for legend. 
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Figure 3. Downregulation of 14-3-3ǅ results in enhanced cell adhesion.  A) Control cells HP2/HP3 and 
14-3-3ǅ downregulated HZ3/HZ4 cells were grown to 80% confluence, trypsinized, pipetted vigorously 
up and down (at least 10x) to prevent clustering in suspension, seeded (106 cells per dish) for the 
indicated time and photographed under phase contrast illumination. B) HP2, HP3, HZ3 and HZ4 cells 
were treated as above, seeded onto 6 cm dishes at 1000 cells per 5 ml medium containing 1 μg/ml 
puromycin and incubated for 2 weeks under standard cell culture conditions. Cell colonies were 
visualized with Coomassie Brilliant Blue (CBB) staining. C) Variation of the total number of HP2, HP3, 
HZ3 and HZ4 colonies relative to the time allowed for plating. Cells were isolated, processed as above, 
seeded for the indicated time period, supplied with fresh medium and incubated for 10 days before 
colonies could be detected by CBB staining and counted. Bars represent standard error. D) Semi-
quantitative RT-PCR analysis of T-cadherin, E-cadherin, Ǆ-catenin, ICAM-1 and GAPDH (control) 
expression at the indicated number of PCR cycles. Note the difference in band intensity between 14-3-
3ǅ downregulated (HZ3/HZ4) and control cells (HP2/HP3) after 25 PCR cycles for T-cadherin and E-
cadherin and at 30 cycles for Ǆ-catenin (see supplementary information for more details). E) Western 
blot showing up-regulation of E-cadherin protein in 14-3-3ǅ downregulated cells (HZ3/HZ4). Total 14-
3-3 and 14-3-3ǅ are included as internal controls (see also Fig. 1). 14-3-3 antibodies were as 
documented in the legend of Fig. 1. For E-cadherin detection a monoclonal antibody from BD 
Transduction Laboratories (Cat. #610181) was used. F) Quantification of E-cadherin expression levels 
in Fig. 3E., indicating a significant increase in E-cadherin proteins in 14-3-3ǅ downregulated cells (HZ) 
versus control cells (HP).  
During culturing of the cell lines, we noticed differences in plating between 14-
3-3ǅ down-regulated and control cells. Control cells attached to the culture dish as 
single cells or clusters of only a few cells, while the 14-3-3ǅ downregulated cells 
appeared to have stronger cell-cell contacts as they clustered in larger groups (Fig. 
3A, 2 hr). In a colony formation assay, 14-3-3ǅ downregulated cells showed 
significantly larger colonies than control cells, although all four cell lines had equal 
growth rates (supplementary figure S1), an observation which corroborates with our 
finding that mitogenic ERK signalling is not affected by 14-3-3ǅ downregulation. 
Apparently, due to enhanced cell-cell contacts, resulting in early clustering, 14-3-3ǅ
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downregulated colonies are initiated by multiple cells in contrast to the control 
colonies (Fig. 3B). Additionally, 14-3-3ǅ downregulated cells attached to the culture 
dish much faster as judged from the flat appearance that was visible already 4 hours 
after seeding, a time point where control cells had still a globular shape (Fig. 3A, 
middle panel). The graphical analysis in Fig. 3C shows that the resulting difference in 
total number of colonies between HZ and HP cells are statistically significant and due 
to early time points of plating. In order to investigate whether these differences 
depend on active processes involving cell adhesion proteins (Balda and Matter, 
2003), we compared the expression levels of intracellular cell adhesion molecule 1 
(ICAM-1), T-cadherin, E-cadherin and Ǆ-catenin between control and 14-3-3ǅ
downregulated cells by RT-PCR analysis. While RNA levels of ICAM-1 were similar in 
all cell lines, RNA levels of adhesion proteins T-cadherin, E-cadherin and Ǆ-catenin 
were significantly higher in 14-3-3ǅ downregulated cells (Fig. 3d).   
 Increased transcription of E-cadherin in these cells was also reflected by 
significantly (approximately 25%) higher protein levels (Fig. 3E, F). Tissue invasion 
and metastasis, like evasion of apoptosis, represents one of the six hallmarks of 
cancer and is directly linked to loss of adhesion proteins (Hanahan and Weinberg, 
2000). Loss of E-cadherin correlates with the invasiveness of human epithelial 
cancers. It has been documented for tumours from various organs and is considered 
a significant prognostic marker (Beavon, 2000). Downregulation of T-cadherin is 
believed to contribute to tumour invasiveness in basal cell carcinomas (Takeuchi et 
al., 2002). Similarly, cancer patients with loss of Ǆ-catenin expression are considered 
a high-risk group for tumour metastasis and poor prognosis (Clairotte et al., 2006; 
Ueda et al., 2006).          
 Taken together, the results described above indicate that the 14-3-3ǅ isoform 
restrains two cellular processes, stress-induced apoptosis and cell adhesion, which 
are also suppressed during carcinogenesis. Hence, we inferred that high expression 
of 14-3-3ǅ might contribute to tumorigenesis. In order to find support for this 
hypothesis, we performed a web-based meta-analysis using the ONCOMINE 
platform, that allows a direct comparison of gene expression profiles in tumours 
versus the corresponding normal tissues (Rhodes and Chinnaiyan, 2005; Rhodes et 
al., 2004). 
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Figure 4.  Overexpression of 14-3-3ǅ in tumours (t = light bars) as compared to the corresponding 
normal tissue (n = dark bars). Data analysis was performed with the ONCOMINE 3.0 database 
(Rhodes and Chinnaiyan, 2005; Rhodes et al., 2004) using standard settings (www.oncomine.org).
The following comparisons were performed: analysis 1) non-tumour liver vs hepatocellular carcinoma, 
2) non-neoplastic lung vs lung adenocarcinoma, 3) normal testis vs seminoma, 4) normal lung vs lung 
adenocarcinoma, 5) normal pancreas vs pancreatic adenocarcinoma, 6) normal lung vs carcinoid, 7) 
normal lung vs squamous cell lung carcinoma. 
 In this analysis, 14-3-3ǅ was clearly up-regulated in human hepatocellular 
carcinoma, seminoma, pancreatic adenocarcinoma and several types of lung 
carcinoma (Fig. 4). Similarly, studies on human stomach cancer (Jang et al., 2004), 
oral squamous cell carcinoma (Arora et al., 2005) and breast cancer (Zang et al., 
2004), have identified 14-3-3ǅ among the most significantly increased proteins/genes 
in the tumours as compared to the corresponding normal tissues. Furthermore, 14-3-
3ǅ maps to human chromosome 8q23, a region frequently amplified in metastatic 
cancer (Ghadimi et al., 2003; Tada et al., 2000).     
 As 14-3-3 proteins are highly homologous, have similar protein structures, 
bind to several binding partners with similar affinities, the most common view so far 
has been that the various isoforms influence particular cellular processes in an 
analogous way (van Hemert et al., 2001). However, the work presented here and 
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recent work by others indicate that individual 14-3-3 proteins possess isoform-
specific functions and might selectively affect distinct aspects of the carcinogenic 
process. Whereas 14-3-3ı is a downstream-target of p53 (Hermeking, 2003) and 14-
3-3Ǆ is an upstream-regulator of p53 (Jin et al., 2006), both isoforms promote DNA 
damage induced cell cycle arrest. On the contrary, overexpression of the 14-3-3ǆ
isoform counteracts the same process (Wanzel et al., 2005). The 14-3-3Ĳ isoform 
stimulates apoptosis by stabilising E2F1 (Wang et al., 2004), whereas the data 
presented here reveal an inhibitory activity of 14-3-3ǅ on UV-induced apoptosis. 
 The cellular phenotypic changes that we have registered are the result of 
downregulation of one specific isoform, without significantly changing the total 
cellular 14-3-3 content. Hence, we infer that the intracellular balance between 14-3-3 
isoforms is crucial for the proper functioning of cells. As mentioned before, the 14-3-
3ı is silenced in many types of cancer and is considered a tumour-suppressor 
(Hermeking, 2003). Downregulation of 14-3-3ǆ was found in glioblastoma and this 
isoform might also act as tumour-suppressor (Buckley et al., 2002). In sharp 
contrast, the data presented here reveal that 14-3-3ǅ is up-regulated in cancer and 
likely behaves as an oncogene. Studies in rodents strongly indicate that also 14-3-3ǃ
has oncogenic properties (Sugiyama et al., 2003; Takihara et al., 2000). In order to 
fully understand how deregulation of the cellular 14-3-3 balance can contribute to 
tumour development, it will be imperative to delineate the precise contribution of 
each 14-3-3 isoform in this process. From the results presented here we anticipate 
that deregulation of the 14-3-3 balance by overexpression of 14-3-3ǅ contributes to 
tumorigenesis by inhibition of apoptosis and cell adhesion.    
 14-3-3 proteins are potential targets for cancer therapeutics (Porter et al., 
2006) and it has been proposed that targeting the 14-3-3 family as a whole might 
reduce the development of resistant tumour cells (Hermeking, 2003). However, if 
deregulation of the intracellular balance between the various isoforms, rather than 
changes of the total cellular 14-3-3 content, is important for tumorigenesis, targeting 
specific isoforms might be more valuable in anticancer therapy. In line with the view 
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presented in this study, preliminary data mentioned by Tzivion et al (Tzivion et al., 
2006) indicate that a slight increase of 14-3-3ǅ is sufficient to induce tumorigenesis 
in mice. Hence, when targeting 14-3-3 for therapeutic purposes, the 14-3-3ǅ isoform 
might be the target of choice in the future.
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Supplementary information 
Supplementary figure S1:
A.          
Figure S1. A. Comparison of growth 
rates between HP2, HP3, HZ3 and HZ4. 
Cells were seeded in two 24-wells 
plates, 104 cells/well, 4 wells/cell line 
and incubated at 5% CO2  at 370C in 
standard medium containing 1 μg/ml 
puromycin. 3 (plate 1) and 4 (plate 2) 
days after seeding, growth medium 
was replaced with growth medium 
containing 50 μg/ml WST-1 (Roche 
Applied Science) and cells were further 
incubated for exactly 4 hours. Wst-1 
reduction was measured in a Tecan 
GENios plate reader at 420nm. Growth 
rates are defined as the increase in 
relative cell number between two 
consecutive days (24 h) and was 
calculated by dividing the average 
OD420 of a cell line measured at day 4 
by the average OD420 of the same cell 
line measured at day 3. Similar results 
were obtained at earlier consecutive 
days.
B. Downregulation of 14-3-3 zeta does 
not influence mitogenic signalling 
cascades. Cells were grown until 50% 
confluence, serum starved for 12 hours 
and treated with medium with serum 
for 30 min (+ serum) or left for the 
same time in DMEM without serum (- 
serum) before extracts were prepared 
and analyzed with phospho-ERK (p-
ERK) or ERK specific antibodies. 
Detection was as described in the 
legend of Fig. 1.  
B.
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Supplementary Methods: 
RT-PCR
RNA isolation and RT-reaction were performed essentially as described previously 
(Niemantsverdriet et al., 2005). Quantitative Real-Time PCR was performed in a 
Biorad iCycler in 25ǋl, using 10 pmol of each primer (see below), SuperTaq+ (HT 
Biotechnologies), SYBR® Green I (Molecular Probes), and Fluorescein (Biorad); 
results were analysed with the iCycler program (Biorad) using dilution series with 
known concentrations of purified target sequence PCR product to calculate the molar 
expression levels. For semi-quantitative RT-PCR, PCR was performed in 50ǋl for the 
indicated amount of cycles, using 20 pmol of gene-specific primers, 1.5mM MgCl
2
 and 
1.25 Units of Amplitaq Gold
TM
 (Roche). Expression levels of 14-3-3 RNA were 
standardised using the expression level of GAPDH. The various PCR primers that 
were used are represented in table 1.
Table 1: Used PCR primers
gene   primer 1     primer 2  
GAPDH   5’- CGGAGTCAACGGATTTGGTCGTAT  5’- AGCCTTCTCCATGGTGGTGAAGAC  
14-3-3ǅ   5’- GCAAGGAGCTGAATTATCCAATG  5’- GTTGTGACTGATCGACAATCCC  
14-3-3Ǉ   5’- AGCAGAAGACCGACACCTCC   5’- CCGTGGTGCAGATGGATC  
14-3-3İ   5’- GAAGAAAACAAGGGAGGAGAAGAC  5’- CTCCGCAGCCTCCTTCC  
14-3-3ǃ   5’- GCAGTCACAGAACAGGGGC   5'- CTATCTTCTCACGGTACTCTTTGC  
14-3-3ǆ   5’- GTGACAGAGCTGAATGAACCTCTC  5’- CCAATTTCTTTTCGTTTCCATC  
Ǆ-catenin  5’- ATGGAGGTGATGAACCTGATGG   5’- CGTTTGGCCCTGGCTG  
T-cadherin  5’- GCCGGTGCCTCTGGAAG   5’- GGCTGTGGCCGTGCCTG  
E-cadherin  5’- TCCATTTCTTGGTCTACGCC   5’- GCCAGGAGAGGAGTTGGG  
ICAM-1   5’- GAGGCTCCGTGCTGGTGAC   5’- CGGTGAGGAAGGTTTTAGCTGTTG 
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Abstract
Nucleocytoplasmic transport of proteins plays an important role in the 
regulation of many cellular processes. Differences in nucleocytoplasmic shuttling can 
provide a basis for isoform-specific biological functions for members of multigene 
families, like the 14-3-3 protein family. Many organisms contain multiple 14-3-3 
isoforms, which play a role in numerous processes, including signalling, cell cycle 
control and apoptosis. It is still unclear whether these isoforms have specialised 
biological functions and whether this specialisation is based on isoform-specific ligand 
binding, expression regulation or specific localisation. Therefore, we studied the 
subcellular distribution of 14-3-3ı and 14-3-3ǅ in vivo in various mammalian cell 
types using yellow fluorescent protein fusions and isoform-specific antibodies. 14-3-
3ı was mainly localised in the cytoplasm and only low levels were present in the 
nucleus, whereas 14-3-3ǅ was found at relatively higher levels in the nucleus. 
Fluorescence recovery after photobleaching (FRAP) experiments indicated that the 
14-3-3 proteins rapidly shuttle in and out of the nucleus through active transport and 
that the distinct subcellular distributions of 14-3-3ı and 14-3-3ǅ are caused by 
differences in nuclear export. 14-3-3ı had a 1.7x higher nuclear export rate constant 
than 14-3-3ǅ, while import rate constants were equal. The 14-3-3 proteins are 
exported from the nucleus at least in part by a Crm1-dependent, leptomycin B-
sensitive mechanism. The differences in subcellular distribution of 14-3-3 that we 
found in this study are likely to reflect a molecular basis for isoform-specific biological 
specialisation.
Key words: 14-3-3 Proteins, 14-3-3 Localisation, Nucleocytoplasmic transport, 
Fluorescence recovery after photobleaching, FRAP 
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Introduction
The 14-3-3 proteins form a family of highly conserved acidic dimeric proteins, 
present in all eukaryotic organisms studied so far (for recent reviews, see Yaffe, 
2002; Tzivion and Avruch, 2002; van Hemert et al., 2001). They are able to associate 
with over 100 binding partners and are involved in the regulation of a wide range of 
cellular processes, including signalling, cell cycle control, apoptosis, exocytosis, 
cytoskeletal rearrangements, transcription and enzyme activity. 
Many organisms contain multiple isoforms – for example, in mammals nine 
isoforms have been identified (Į, ǃ, Ǆ, į, İ, ǅ, ǆ and ı), but the reason for this 
variety remains unclear. It is not yet understood whether isoforms have distinct and 
specialised functions or whether they are just under the control of temporal and 
tissue specific regulation. Variations in temporal, developmental and tissue-specific 
isoform expression have indeed been reported (Yaffe, 2002; Leffers et al., 1993; 
Rittinger et al., 1999; Roth et al., 1994; Perego and Berruti, 1997; Tien et al., 1999). 
In addition, the expression of several plant and mammalian isoforms is influenced by 
external stimuli like temperature, injury and different types of stress (Yaffe, 2002; 
Jarillo et al., 1994; de Vetten and Ferl, 1995; Chen et al., 1994; Kidou et al., 1993). 
Besides differences in expression patterns, there are several reports on isoform-
specific interactions with 14-3-3 binding partners (Yaffe, 2002; Wakui et al., 1997; 
Craparo et al., 1997; Meller et al., 1996; Liu et al., 1997; Van Der Hoeven et al., 
2000; Tang et al., 1998; Peng et al., 1997; Zhang et al., 1997; Kumagai et al., 1998; 
Kurz et al., 2000; Hashiguchi et al., 2000). However, many functions can be 
performed by all 14-3-3 isoforms. Several binding partners, like Raf-1, BAD and Cbl, 
associate with all isoforms (Yaffe, 2002; Rittinger et al., 1999; Subramanian et al., 
2001), and several 14-3-3-associating peptides have similar affinities for all isoforms 
(Muslin et al., 1996; Petosa et al., 1998). It is therefore likely that a combination of 
isoform-specific expression, localisation and functional specialisation is the basis for 
the existence of multiple isoforms.  
In this report we focus on the human ı and ǅ isoforms. 14-3-3ǅ is abundant in 
various tissues and has been reported to interact with many of the known 14-3-3 
ligands. 14-3-3ı (also called stratifin) is mainly expressed in epithelial cells (Leffers 
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et al., 1993) and is strongly induced by ionising radiation and DNA damage through a 
p53-responsive promoter element (Hermeking et al., 1997). In addition, it is involved 
in differentiation of keratinocyte stem cells (Pellegrini et al., 2001). 14-3-3ı appears 
to be involved in oncogenesis as it is downregulated in many breast cancers 
(reviewed by Yaffe, 2002) and hepatocellular carcinoma cells (Iwata et al., 2000), 
and it is overexpressed in several other cancers (Yaffe, 2002). 14-3-3ı acts as a 
tumor suppressor, inducing a G1 arrest by inhibiting Cdk2 and causing a G2 arrest by 
sequestering cyclin B1-cdc2 in the cytoplasm (Laronga et al., 2000; Chan et al., 
1999; Hermeking et al., 1997). In contrast to 14-3-3ǅ and other isoforms, 14-3-3ı
does not bind to CDC25 (Peng et al., 1997).
Several 14-3-3 isoforms have been reported to be abundant in the cytoplasm 
and to be present in the nucleus of various organisms (Todd et al., 1998; Markiewicz 
et al., 1996; Fanger et al., 1998; Kumagai and Dunphy, 1999; Dalal et al., 1999; van 
Zeijl et al., 2000). 14-3-3s were also found to be associated with membranes (Martin 
et al., 1994; Roth et al., 1994; Jones et al., 1995; Tien et al., 1999), the cytoskeleton 
(Garcia et al., 1999; Ku et al., 1998; Roth and Burgoyne, 1995; Roth et al., 1994) 
and centrosomes (Pietromonaco et al., 1996). Some reports suggested a specific 
subcellular distribution for certain isoforms (Roth et al., 1994; Martin et al., 1994; 
Sehnke et al., 2000; Pietromonaco et al., 1996). However, a detailed comparison of 
isoform-specific localisation in one system has not been performed and all published 
studies are based on immunolocalisations in fixed cells. Here, we report on the 
isoform-specific and dynamic localisation of 14-3-3ı and 14-3-3ǅ in living mammalian 
cells. We used yellow fluorescent protein (YFP) fusion constructs and showed that 
these were functional in vivo in yeast. We found that 14-3-3ı had a mainly diffuse 
cytoplasmic distribution in various mammalian cell types and that only low levels 
were present in the nucleus. By contrast, 14-3-3ǅ was present at higher levels in the 
nucleus. We showed that both 14-3-3 proteins rapidly shuttle in and out of the 
nucleus, in part via a Crm1-mediated nuclear export mechanism. We performed 
fluorescence recovery after photobleaching (FRAP) experiments on living cells from 
which we conclude that a difference in nuclear export causes the different subcellular 
distributions of 14-3-3ı and 14-3-3ǅ.
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Materials and Methods
Strains, media and cell culture 
The Saccharomyces cerevisiae strains used in this study were derived from 
GG1306 (MATa leu2,3-112 ura3-52 trp1-92 his4 bmh1::LEU2 bmh2::APT1 
Ycplac33[BMH2] (van Heusden et al., 1995)). Yeast strains were grown at 30°C in 
either MY or MYZ with 1% galactose (Zonneveld, 1986), supplemented as required 
with 30 μg/ml uracil, 20 μg/ml tryptophan, 20 μg/ml histidine and 1 mg/ml 5-
fluoroorotic acid (5-FOA). Yeast was transformed according to the method of Gietz et 
al. (Gietz et al., 1995). NHK cells (normal human keratinocytes) were grown as 
described previously (Sark et al., 1998). Hela, HaCaT, NIH-3T3 and NHF cells 
(normal human fibroblasts, strain F9) were cultured in a 1:1 mixture of Dulbecco's 
modified Eagle's medium (DMEM) and Ham's F10, supplemented with 10% fetal 
bovine serum (Hyclone), streptomycin and penicillin.  
Plasmids 
The sequences of the oligonucleotides used in this study are listed in Table 1.  
Table 1. Oligonucleotide sequences 
P1  5’-CCGATGGATCCATGGAGAGAGCCAGTCTGATC – 3’   
P2  5’-CTATGGATCCCCGCCACCGCTCTGGGGCTCCTGGGGAG – 3’   
P3  5’-CGCGCGGATCCATGGATAAAAATGAGCTGGTTC – 3’   
P4  5’-CGCGGATCCCCGCCACCATTTTCCCCTCCTTCTCCTG – 3’   
P5  5’-AGCTGAATTCCTCGAGATGAGAGGTTCTCATCACCATCACCATCACGGGGAATTCCCGGCTAGAAGCTTTA 
 AGCGGCCGC – 3’   
P6  5’-CTAGGCGGCCGCTTAAAGCTTCTAGCCCGGGAATTCCCCGTGATGGTGATGGTGATGAGAACCTCTCATCT 
 CGAGGAATTC – 3’   
P7  5’-AATTAATAAAAAAATAATGGAGAGAGCCAGTCTGATCCAGAAGGCCAAGCTGGCAGAGCAGGCCGAACG 
CTATGAGGACATGGCAGCCTTCATGAAAGG – 3’   
P8  5’-CGCCTTTCATGAAGGCTGCCATGTCCTCATAGCGTTCGGCCTGCTCTGCCAGCTTGGCCTTCTGGATCAGAC 
TGGCTCTCTCCATTATTTTTTTATT – 3’   
P9  5’-GGGGTACCAAAAAATGGATAAAAATGAGCTGGTTC – 3’   
P10  5’-GCTCTAGATTAATTTTCCCCTCCTTCTCC – 3’   
P11  5’-AATTAGATCTAAAAATAATGCGAGGTTCTCATCACCATCACCATCACGG – 3’   
P12  5’-CCGTGATGGTGATGGTGATGAGAACCTCGCATTATTTTTAGATCT – 3’   
P13  5’-AGCTGAATTCCCGGGCTAGAAGCTTTAAGCGGCCGC – 3’   
P14  5’-CTAGGCGGCCGCTTAAAGCTTCTAGCCCGGGAATTC – 3’   
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Plasmids pMP4553 and pMP4558 encode 14-3-3ı and 14-3-3ǅ, respectively, 
tagged C-terminally with YFP and under the control of the CMV promoter. pMP4552 
and pMP4553 were constructed by cloning a fragment generated by PCR with 
primers P1 and P2 on a human keratinocyte cDNA library (Marenholz et al., 2001), 
followed by digestion with BamHI, in pECFP-N1 and pEYFP-N1 (Clontech), 
respectively. A similar strategy was used to construct pMP4557 and pMP4558, which 
encode 14-3-3ǅ, C-terminally tagged with CFP and YFP, respectively. For the latter 
constructs, a fragment generated by PCR with primers P3 and P4 on I.M.A.G.E. 
Consortium (LLNL) cDNA Clone 531246 (Lennon et al., 1996), followed by digestion 
with BamHI, was used as insert. pYES-TRP[BMH2] allows the galactose inducible 
expression of BMH2 (van Heusden et al., 1996). Yeast expression vector pMP4550, 
containing the TRP1 marker and the GAL1 promoter, was constructed by replacing 
the URA3 gene of pYES2 (Invitrogen) with a 1.8 kb TRP1 containing ClaI-BglI 
fragment from YEplac112 (Gietz and Sugino, 1988). Plasmid pMP4570 enables the 
galactose inducible expression of 14-3-3ı. This plasmid was made by inserting a 
synthetic DNA fragment consisting of oligonucleotides P5 and P6 in the HindIII-XbaI 
sites of pMP4550, followed by cloning a 0.8 kb 14-3-3ı containing SalI-BsrBI 
fragment from pMP4552 in the XhoI-SmaI sites of the resulting construct. 
Subsequently, a synthetic DNA fragment consisting of oligonucleotides P7 and P8 
was cloned in the EcoRI-NarI sites of this plasmid to improve expression. Plasmid 
pMP4585 enables the galactose inducible expression of 14-3-3ǅ in yeast. A fragment 
containing 14-3-3ǅ flanked by KpnI and XbaI sites generated by PCR on pMP4558 
with primers P9 and P10 was cloned in the KpnI-XbaI sites of pMP4550. pMP4581 
encodes a YFP and 6xHis-tagged 14-3-3ı under control of the GAL1 promoter and 
was constructed by cloning a 14-3-3ı-YFP-containing XmaI-NotI fragment from 
pMP4553 in pMP4571, after which a synthetic DNA fragment consisting of 
oligonucleotides P11 and P12 was inserted in the EcoRI-SmaI sites of this plasmid. 
pMP4583, which encodes 6xHis-14-3-3ǅ-YFP, was made in an analogous way, except 
that a 1.25 kb 14-3-3ǅ-YFP-containing XmaI-NotI fragment from pMP4558 was used. 
Replacement of a 1.25 kb XmaI-NotI of pMP4583 with a 14-3-3ǅ-CFP containing 
XmaI-NotI fragment from pMP4557 yielded plasmid pMP4587. Plasmid pMP4584, 
which allows the expression of 6xHis-14-3-3ı-CFP in yeast, was made by inserting a 
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synthetic DNA fragment consisting of oligonucleotides P13 and P14 in the HindIII-
XbaI sites of pMP4550, followed by cloning a 1.4 kb 14-3-3ı-CFP containing SfiI-NotI 
fragment from pMP4552 in the SfiI-NotI sites of the resulting plasmid.  
Purification and analysis of recombinant 14-3-3 proteins 
Yeast strains expressing various human 14-3-3 fusion proteins were grown in 
MYZ, 1% galactose, uracil, histidine to an OD620 of 0.5. All steps were performed at 
4°C. Cells were lysed with glass beads in FastProtein Red tubes (Bio101) with a 
Fastprep FP120 (Bio101) in 50 mM Tris-HCl pH 8, 300 mM NaCl, 1% triton X-100, 
Mini Complete protease inhibitors, EDTA free (Roche) and 5 mM sodium-
orthovanadate. Lysates were cleared by centrifugation and applied to a Ni2+-NTA 
agarose (Qiagen) column. The column was washed with 50 mM Tris-HCl pH 8, 300 
mM NaCl, followed by a gradient of 10-50 mM imidazole in the same buffer. Elution 
was done with 500 mM imidazole in 50 mM Tris-HCl pH 6.5, 300 mM NaCl. The 
eluted protein was dialysed twice against 500 volumes of 50% glycerol, 50 mM Tris-
HCl pH 7.6, 300 mM NaCl, 1 mM DTT. Concentrations were determined by Bradford 
analysis and purity was estimated by SDS-PAGE followed by Coomassie staining. Gel 
filtration analysis of purified proteins was done with a 70 ml Sephacryl S200 column 
(Pharmacia) on a BioLogic system (Biorad), using molecular weight standards 
(Sigma) for calibration.  
Cellular fractionation and western blot analysis 
HaCaT cells were fractionated into nuclear extract and cytosol using the 
method of Brunet et al. (Brunet et al., 2002). Five micrograms of total protein from 
the cytosolic and nuclear extract were separated by 12% SDS-PAGE and proteins 
were transferred to PVDF by semi-dry blotting in 39 mM glycine, 48 mM Tris, 0.08% 
SDS, 20% methanol. 14-3-3ı and 14-3-3ǅ were detected with specific antibodies (N-
14 and C-16, respectively) from Santa Cruz Biotechnology. No cross-reactivity was 
found with these antibodies in a test with purified 14-3-3 proteins. Antibodies against 
actin (C-2), Į-tubulin (B-7), PKC (C-20), RasGAP (B4F8) and p53 (DO-1) (Santa Cruz 
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Biotechnology) were used in control experiments. All antibodies were diluted 1:1000. 
The BM Chemiluminescence Western Blotting Kit (Roche-Boehringer) was used for 
detection. Yeast protein extracts were subjected to immunoblotting as described 
above, except that Pan 14-3-3 antibodies were used to detect human 14-3-3 
isoforms and anti-Bmh1p antiserum (van Heusden et al., 1995) was used to detect 
yeast 14-3-3 proteins. Antisera were diluted 1:5000.
Localisation of YFP-labelled 14-3-3 isoforms 
Various mammalian cells were transfected with pMP4553, pMP4558 or pEYFP-
N1 using DOTAP (N-[1-(2,3-dioleoyloxy)]-N,N,N-trimethylammoniumpropane-
methylsulfate) (Roche). When desired, 20 ng/ml leptomycin B (LMB) was added to 
the medium 24 hours after transfection and cells were analysed at 0, 2, 4, 5 and 24 
hours after addition with a Leica TCS NT confocal microscope. YFP was excited at 
514 nm and emission was detected at 526-595 nm. Nuclear and cytoplasmic 14-3-3 
levels were determined by quantifying the average YFP fluorescence of regions in the 
nucleus and cytoplasm of a z-section through the middle of the nucleus using the 
ImageJ program. The FN/FC ratio was calculated by dividing the nuclear value by the 
cytoplasmic value.
Immunofluorescence microscopy 
HaCaT and Hela cells were grown on glass coverslips, fixed with 
methanol:acetic acid (3:1) and permeabilized with 50 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 0.25% gelatine, 0.5% Triton X-100. Cells were stained overnight with specific 
anti-14-3-3ı (N-14) or anti-14-3-3ǅ (C-16) antibodies (Santa Cruz Biotechnology), 
diluted 1:10. The primary antibody was omitted in control experiments. After 
washing three times, the coverslips were incubated three hours with Alexa-568 
donkey anti-goat IgG (Molecular Probes) or Alexa-568 goat anti-rabbit IgG (Molecular 
Probes), diluted 1:50. After washing five times with PBS, cells were analysed with a 
Leica TCS NT confocal microscope. Alexa-568 was excited at 568 nm and emission 
was detected at 590-635 nm. Image analysis and quantification were done as 
described previously for YFP-labelled isoforms.  
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FRAP analysis 
Fluorescence recovery after photobleaching (FRAP) experiments were done on 
a Leica TCS NT confocal microscope. YFP was excited at 514 nm at a laser power of 
0.8 mW and emission was detected at 526-595 nm. After recording a pre-bleach 
image, a region covering >75% of the nucleus was photobleached by zooming in 
and scanning at high speed with maximum laser power (8 mW) for 3 seconds. 
Subsequently, images were captured at 1-second intervals during 2 minutes for YFP-
labelled 14-3-3 proteins or at 4-second intervals during 8 minutes for YFP alone. 
During recording of the pre-bleach and time-lapse images, no significant 
photobleaching was observed for cells for which the photobleaching step was 
omitted. The change in nuclear fluorescence signal over time (FN(t)) was quantified 
by image analysis with the LCS-NT software (Leica). FN(t) was normalised such that 
FN=0 corresponds to the level of fluorescence immediately after photobleaching and 
FN=1 corresponds to the final level of fluorescence at the end of the experiment. 
From the steady-state intensity distribution of nuclear (FN) versus cytosolic 
fluorescence signal (FC), the ratio of nuclear import (ki) and nuclear export rate 
constant (ke) was calculated using ki/ke=FN/FC. For analysis of the fluorescence 
recovery, we assumed that the nuclear volume was much smaller than the cytosolic 
volume, which means that FC is constant and independent of the photobleaching 
process (actually we found that FC decreased by <10%). Furthermore, it was 
assumed that photobleaching does not influence the import and export rates of 14-3-
3. In this case exchange of photobleached molecules is governed by ke and the 
process can be described by a first-order rate equation leading to a fluorescence 
recovery of FN(t)=1-e-ket. Data were fit to this equation leading to a value for ke, and 
in combination with the steady-state distribution to the import rate constant 
ki=ke·FN/FC. The half time Ĳ(1/2), the time required to reach 50% recovery, was 
calculated using Ĳ1/2=ln 2/ke. All calculations were based on measurements on at 
least 15 cells from two independent experiments.  
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Results   
Recombinant YFP- and CFP-labelled human 14-3-3 proteins are 
functional in yeast
We set out to study the 14-3-3ı and 14-3-3ǅ  proteins in living human cells by 
making CFP and YFP fusion proteins. To test whether these are functional, we used a 
yeast-based assay. Disruption of the yeast 14-3-3 genes BMH1 and BMH2 is lethal 
and can be complemented by genes encoding 14-3-3 proteins from other organisms 
(van Heusden et al., 1995; van Heusden et al., 1996). Yeast strain GG1306 contains 
a bmh1 bmh2 disruption, which is complemented by the BMH2 gene on plasmid 
YCplac33[BMH2]. This strain was transformed with plasmids encoding wild-type and 
various recombinant 14-3-3ı or 14-3-3ǅ isoforms under the control of the galactose-
inducible GAL1 promoter (Fig. 1A, left panel). The resulting strains were transferred 
to minimal medium containing galactose, 5-FOA, uracil and histidine, on which they 
can only grow when they are able to lose plasmid YCplac33[BMH2]. Strains 
expressing human 6xHis-14-3-3ǅ-CFP or 6xHis-14-3-3ǅ-YFP grow as good as cells 
expressing the yeast Bmh2p protein (Fig. 1A, right panel), indicating that these 14-3-
3 isoforms can complement the bmh1 bmh2 disruption. Human 14-3-3ı constructs 
also complement, although strains expressing these proteins grow slower compared 
with strains expressing Bmh2p or 14-3-3ǅ. A strain carrying the empty vector (Fig. 
1A, strain 1) was not able to grow on 5-FOA containing medium. To rule out the 
possibility that mutations in the URA3 gene of plasmid Ycplac33[BMH2] enabled 
strains to grow on medium with 5-FOA, we checked for the absence of plasmid 
Ycplac33[BMH2] by PCR. A 400 bp product is formed with plasmid Ycplac33[BMH2] 
as template and a 600 bp internal control product is formed with the genomic bmh2 
locus as template. Before 5-FOA treatment, both products were obtained (Fig. 1B, 
glucose). After 5-FOA treatment the 400 bp product was absent, while the 600 kb 
control product was still present (Fig. 1B), indicating the absence of Ycplac33 
[BMH2]. In addition, the absence of the yeast 14-3-3 proteins in strains growing on 
5-FOA was shown by western blotting with an antibody against Bmh1p and Bmh2p 
(Fig. 1C). The clear band present in a strain expressing Bmh2p (Fig. 1C, strain 2) is 
66
Nucleocytoplasmic shuttling of 14-3-3 
absent in the strains expressing human isoforms. The presence and expression level 
of recombinant human 14-3-3 isoforms was investigated by western blotting with a 
Pan 14-3-3 antiserum. The yeast Bmh2 protein was not recognised by this antiserum 
(Fig. 1D, lane 2). The mobility of 14-3-3ı, 14-3-3ǅ and the 6xHis-tagged CFP and 
YFP fusion proteins was in agreement with their predicted mass (Fig. 1D, lane 3-8). 
Figure. 1. Recombinant human 14-3-3 proteins complement the lethal disruption of yeast 14-3-3 
genes. (A) GG1306-derived yeast strains expressing the indicated 14-3-3 isoforms were transferred 
from glucose medium (left) to 5-FOA-containing medium (right). Strains can only grow on this 
medium when they are able to lose plasmid YCplac33[BMH2], illustrating the ability of the foreign 14-
3-3 isoform to take over the function of the yeast 14-3-3 proteins. (B) The absence of plasmid 
Ycplac33[BMH2] after 5-FOA treatment was determined by PCR. This plasmid yields a 400 bp product, 
besides a 600 bp internal control product. Western blots on 5 μg (C) or 2.5 μg (D) total protein from 
strains after 5-FOA treatment with an antiserum against yeast 14-3-3 proteins (C) or against Pan 14-
3-3 proteins (D). Lane b contains 20 ng purified Bmh2p. 
14-3-3ı constructs had slightly lower expression levels compared with 14-3-3ǅ
constructs, which might explain the slower growth of strains complemented by 14-3-
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3ı. Expression levels of the recombinant 14-3-3s were estimated to be 1-2% of total 
protein. These results show that solely the human recombinant 14-3-3 isoforms are 
responsible for the complementation of the lethal bmh1 bmh2 disruption in yeast 
cells. Our data indicate that human recombinant 14-3-3 proteins are functional in 
yeast and that an N-terminal 6xHis-tag and a C-terminal CFP or YFP fusion do not 
interfere with at least the essential 14-3-3 function(s).
6xHis-14-3-3ı-CFP forms dimers and associates with a Raf-1-
based peptide 
6xHis-tagged CFP and YFP fusions of 14-3-3ı and 14-3-3ǅ were purified from 
yeast to a purity of more than 95%. The proteins had a molecular mass of 57 kDa in 
SDS-PAGE (Fig. 2A), which corresponds to the predicted molecular mass of a 
monomer. Gelfiltration of purified 6xHis-14-3-3ı-CFP yielded an elution profile with a 
single peak corresponding to a mass of 116 kDa (Fig. 2B).
Figure. 2. Recombinant human 14-3-3 isoforms form dimers. (A) Coomassie-stained polyacryl-amide 
gel of recombinant human 14-3-3 isoforms purified from yeast. (B) Gel filtration analysis of 6xhis-14-
3-3ı-CFP. 
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This indicates that the protein forms dimers and that dimerisation is not affected by 
the introduction of an N-terminal 6xHis-tag near the dimerisation domain. For the 
other 14-3-3 fusion proteins similar results were obtained (data not shown).  
Both 14-3-3ı-YFP and 14-3-3ǅ-YFP bound a Raf-1-based peptide with similar affinity 
as the yeast 14-3-3 protein Bmh2p in fluorescence correlation spectroscopy 
measurements (R. Schmauder, unpublished). This suggests that the C-terminal YFP 
fusion does not interfere with 14-3-3-ligand interactions.
14-3-3ı and 14-3-3ǅ have a different subcellular distribution 
To study the subcellular distribution of 14-3-3 isoforms we transiently 
transfected various mammalian cell types and determined the localisation of 14-3-3ı-
YFP and 14-3-3ǅ-YFP. Control experiments, in which transfected and untransfected 
cells were immunostained, showed that transfection had no effect on the distribution 
of endogenous 14-3-3ı and 14-3-3ǅ (data not shown). In all cell types investigated, 
14-3-3ı had a mainly diffuse cytoplasmic distribution and only low levels of 
fluorescence were observed in the nucleus (Fig. 3A, left panel). The intracellular 
distribution of 14-3-3ǅ-YFP was clearly different. A diffuse cytoplasmic and nuclear 
localisation was observed, although fluorescence in the nucleus was slightly lower 
than in the cytoplasm (Fig. 3A, right panel). Nuclear (FN) and cytoplasmic (FC) 14-3-3 
levels were determined and the ratio FN/FC was calculated for each cell type (Fig. 
3B). 14-3-3ı and 14-3-3ǅ had a clearly distinct intracellular distribution in all cell 
types investigated. The FN/FC ratio of 14-3-3ǅ was about twice that of 14-3-3ı.
Immunolocalisation of endogenous 14-3-3ı and 14-3-3ǅ with specific antibodies in 
HaCaT and Hela cells revealed similar subcellular distributions as were found with the 
14-3-3-YFP constructs (Fig. 3B; Fig. 3C, hatched bars). This indicates that results 
obtained with YFP-labelled 14-3-3 isoforms have biological significance.  
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Figure. 3. (A) Subcellular distribution of 14-3-3ı-YFP and 14-3-3ǅ-YFP in the indicated mammalian 
cells. (B) HaCaT and Hela cells immunostained for endogenous 14-3-3ı and 14-3-3ǅ. (C) Quantitative 
analysis of the subcellular distribution of 14-3-3ı (light) and 14-3-3ǅ (dark). Solid bars represent the 
average nuclear/cytoplasmic (FN/FC) ratio obtained with YFP-labelled 14-3-3 isoforms. Hatched bars 
represent the quantitative analysis of immunolocalisations of endogenous 14-3-3ı and ǅ. Standard 
deviations are indicated (black lines). 
We further investigated the subcellular distribution of 14-3-3 by biochemical 
fractionation of HaCaT cells into a cytosolic and nuclear extract. Equal amounts of 
total protein from both extracts were analysed by western blotting with specific 
antibodies for 14-3-3ı (Fig. 4A) and 14-3-3ǅ (Fig. 4B). 14-3-3ı appears to be mainly 
cytosolic, although a small amount can be seen in the nucleus (not visible in this 
exposure) when more protein is loaded (data not shown). The majority of 14-3-3ǅ is 
cytosolic, but a significant amount is present in the nucleus (Fig. 4B). A control 
experiment with antibodies against known nuclear (p53), cytoplasmic (RasGAP, PKC) 
and cytoskeletal (actin, -tubulin) proteins shows that the nuclear extract is not 
contaminated with cytoplasmic or cytoskeletal proteins and that the cytosolic fraction 
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is not contaminated with nuclear proteins (Fig. 4C). These data confirm the results 
from microscopic analysis.
Figure. 4. Subcellular distribution of 14-3-3 after biochemical cell fractionation. HaCaT cells were 
fractionated into a cytosolic (C) and nuclear extract (N). Equal amounts of total protein from both 
extracts were analysed by western blotting. (A) Blot stained with specific 14-3-3ı antibodies or (B) 
specific 14-3-3ǅ antibodies. (C) Control probed with antibodies against known nuclear (p53), 
cytoplasmic (RasGAP, PKC) and cytoskeletal (actin, -tubulin) proteins. 
Crm1-dependent export of 14-3-3ı and 14-3-3ǅ
Both 14-3-3ı and 14-3-3ǅ contain a putative nuclear export sequence (NES). 
Therefore, we studied the effect of the Crm1-dependent nuclear export inhibitor LMB 
on the intracellular 14-3-3 distribution. Treatment of HaCaT cells expressing 14-3-3ı-
YFP with LMB led to a clear increase in nuclear 14-3-3ı concentration (Fig. 5A). For 
14-3-3ǅ, a similar increase in nuclear concentration was observed, although the 
effect appeared to be less strong. The nuclear accumulation of 14-3-3ı and 14-3-3ǅ
had already reached its maximum 2 hours after LMB treatment and no significant 
changes were observed 4, 5 and 24 hours after the addition of LMB. A fraction of 
cells appeared relatively unresponsive to LMB treatment. We calculated the FN/FC
ratio for 50 HaCaT cells expressing either 14-3-3ı-YFP or 14-3-3ǅ-YFP, with and 
without LMB treatment (Fig. 5B). Untreated cells expressing 14-3-3ı-YFP had an 
average FN/FC of 0.31±0.07. Subsequently, the percentage of cells with an FN/FC
ratio higher than 0.45 (average FN/FC plus two times standard deviation of untreated 
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cells) was calculated (Fig. 5C). Untreated cells expressing 14-3-3ǅ-YFP had an 
average FN/FC of 0.59±0.09, and therefore we calculated the percentage of cells with 
FN/FC >0.77 for 14-3-3ǅ (Fig. 5C).
Figure. 5. Effect of LMB on intracellular 14-3-3ı and 14-3-3ǅ distribution. (A) HaCaT cells expressing 
14-3-3ı-YFP or 14-3-3ǅ-YFP were incubated in medium with or without LMB for 5 hours. (B) Plot of 
the individual FN/FC ratios for 14-3-3ı-YFP and 14-3-3ǅ-YFP of 50 cells, with and without LMB 
treatment. (C) Percentage of cells with a significantly increased FN/FC ratio (FN/FC>0.45 for 14-3-3ı
and FN/FC>0.77 for 14-3-3ǅ). (D) HaCaT cells incubated in medium with or without LMB for 5 hours 
were immunostained with specific antibodies for 14-3-3ı or 14-3-3ǅ. (E) Plot of the individual FN/FC
ratios for endogenous 14-3-3ı and 14-3-3ǅ of cells treated with and without LMB. (F) Percentage of 
cells with a significantly increased FN/FC ratio of endogenous 14-3-3 (FN/FC>0.31 for 14-3-3ı and 
FN/FC>0.64 for 14-3-3ǅ).
To study the effect of LMB treatment on the subcellular distribution of 
endogenous 14-3-3 proteins, we immunostained untreated and LMB-treated HaCaT 
cells with antibodies specific for 14-3-3ı or 14-3-3ǅ (Fig. 5D). LMB treatment led to a 
noticeable increase in nuclear 14-3-3 concentration. As described above, we 
determined the FN/FC ratio for individual cells immunostained for either 14-3-3ı or 
14-3-3ǅ, with and without LMB treatment (Fig. 5E). Subsequently, the percentage of 
cells with an FN/FC ratio higher than 0.31 for 14-3-3ı and higher than 0.64 for 14-3-
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3ǅ was calculated (Fig. 5F). As was found with the YFP-labelled isoforms, LMB 
treatment appeared to have a stronger effect on the nuclear accumulation of 14-3-
3ı than that of 14-3-3ǅ.
Our data show that LMB treatment leads to a significant increase in nuclear 
14-3-3 levels, indicating that 14-3-3 is exported at least in part by a NES- and Crm1-
dependent mechanism. The fact that LMB treatment leads to a significant, but not 
complete accumulation of 14-3-3 in the nucleus, suggests that, besides Crm1-
dependent export, other export mechanisms are also involved. A fivefold higher LMB 
concentration did not result in increased nuclear accumulation (data not shown), 
which is in line with the findings of others that the LMB concentrations used in this 
study are sufficient to give an almost complete inhibition of Crm1.  
Nuclear import and export rates of 14-3-3ı and 14-3-3ȗ
Why do 14-3-3ı and 14-3-3ǅ have a different subcellular distribution? 14-3-3ı
is either imported more slowly or exported more rapidly than 14-3-3ǅ. To investigate 
this aspect, we studied the nuclear import and export of 14-3-3ı and 14-3-3ǅ using 
FRAP in the presence and absence of LMB. A region covering >75% of the nucleus of 
HaCaT cells expressing 14-3-3ı-YFP, 14-3-3ǅ-YFP or YFP alone was photobleached 
for 3 seconds, after which fluorescence recovery in the nucleus was followed over 
time (Fig. 6A). Photobleaching a square region in the nucleus for 3 seconds did not 
lead to a discrete square photobleached zone, but resulted in a homogenous 
decrease in fluorescence throughout the entire nucleus (Fig. 6A). This shows that the 
14-3-3 proteins are highly mobile within the nucleoplasm and therefore that the 
observed relatively slow fluorescence recovery in the nucleus is the result of 
exchange of photobleached molecules for fluorescent molecules from the cytoplasm. 
Time-dependent recovery of nuclear fluorescence was quantified and the nuclear 
import (ki) and export (ke) rate constants and half-times (1/2) were determined as 
described in Materials and Methods. Repeated photobleaching of the nucleus of the 
same cell yielded similar half-times (data not shown), indicating that the 
photobleaching process did not affect the import-export process.
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Figure. 6. FRAP analysis of nucleocytoplasmic transport of 14-3-3 proteins. (A) A region covering 
>75% of the nucleus (indicated by the white box) of HaCaT cells expressing 14-3-3ı-YFP or 14-3-3ǅ-
YFP was photobleached, after which images were recorded at 1-second intervals. Fluorescence 
recovery is shown for two representative cells at the indicated times in seconds. (B) Typical 
normalised recovery curves with Ĳ1/2 for nuclear export for 14-3-3ı-YFP, 14-3-3ǅ-YFP and YFP alone. 
(C) Rate constants for the nuclear import and export of 14-3-3ı-YFP, 14-3-3ǅ-YFP and YFP alone, in 
untreated and LMB-treated cells. At least 15 cells were measured and quantified in each experiment. 
Typical normalised recovery curves for 14-3-3ı-YFP, 14-3-3ǅ-YFP and the YFP 
control are shown in Fig. 6B. A Ĳ1/2 of 5.7±1.5 seconds and 9.7±1.5 seconds was 
found for the nuclear export of 14-3-3ı-YFP and 14-3-3ǅ-YFP, respectively. For 
nuclear import, a Ĳ1/2 of 18 seconds was found for both 14-3-3ı-YFP and 14-3-3ǅ-
YFP. As the ke of 14-3-3ı is 1.7 times higher than the ke of 14-3-3ǅ, while the kis are 
equal, the different subcellular distribution of 14-3-3ı compared with 14-3-3ǅ
appears to be caused by the more efficient export of 14-3-3ı. Comparing these 
values to the Ĳ1/2 of 61±15 seconds for the passive diffusion of YFP alone suggests 
that the 14-3-3 proteins shuttle rapidly in and out of the nucleus through active 
transport. To ensure that the results from our FRAP experiments reflect nuclear 
export of 14-3-3, we performed FRAP experiments on cells treated with the nuclear 
export inhibitor LMB. Fig. 6C shows the kis and kes for 14-3-3ı-YFP, 14-3-3ǅ-YFP and 
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YFP alone in untreated and LMB-treated cells. LMB treatment reduced the ke for 14-
3-3ı export by 45% and by 30% for 14-3-3ǅ (Fig. 6C). The kis (calculated from the 
ke and the increased FN/FC) were not significantly reduced after LMB treatment. This 
suggests that 14-3-3ı and, to a lesser extent, 14-3-3ǅ are exported at least in part 
by a Crm1-dependent mechanism.
Discussion
Nucleocytoplasmic transport of proteins plays an important role in the 
regulation of many cellular processes. Differences in the kinetics of nuclear shuttling 
can provide a basis for isoform-specific functional specialisation of members of 
multigene families. This is particularly significant for conserved protein families, like 
the 14-3-3 proteins. Many organisms contain multiple 14-3-3 isoforms and, thus far, 
it remains unclear whether and to what extent these isoforms have specialised 
biological functions and whether these are based on temporal and tissue-specific 
expression regulation and/or on isoform-specific ligand binding. In addition, 
ambiguous and conflicting data have been reported on the specific subcellular 
distribution of isoforms (Roth et al., 1994; Martin et al., 1994; Sehnke et al., 2000; 
Pietromonaco et al., 1996). To gain more insight in this matter, we studied the 
subcellular distribution and dynamic localisation of 14-3-3ı and 14-3-3ǅ in living 
mammalian cells.
We first showed that recombinant human 14-3-3-YFP constructs are functional 
in vivo in yeast, that they form dimers in vitro and are able to bind a Raf-1-based 
peptide. This suggests that the fusion of YFP to the C-terminus and a 6xHis-tag to 
the N-terminus of 14-3-3 does not interfere with the major 14-3-3 functions.  
The subcellular distribution of 14-3-3ı and 14-3-3ǅ was studied in various 
mammalian cell types by immunostaining endogenous 14-3-3 proteins with specific 
antibodies and by analysis of cells transiently expressing YFP fusions of these 
proteins. Biochemical fractionation of HaCaT cells provided additional insight in the 
isoform-specific subcellular distribution of the 14-3-3 proteins. 14-3-3ı exhibited a 
mainly diffuse cytoplasmic distribution and was present at low levels in the nucleus. 
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But nuclear concentrations of 14-3-3ǅ-YFP were noticeably higher in comparison with 
14-3-3ı. FN/FC ratios of 0.26 and 0.52 were found for 14-3-3ı and 14-3-3ǅ,
respectively. No significant differences in subcellular distribution were found between 
the various cell types, indicating that the mechanism responsible for the more 
efficient nuclear exclusion of 14-3-3ı is unlikely to be cell-type specific, as it is even 
present in cell types that normally do not express 14-3-3ı (e.g. NIH-3T3 and NHF).  
We performed FRAP experiments on living cells to study the mechanism 
underlying the different subcellular distributions of 14-3-3ı and 14-3-3ǅ. Both 14-3-
3ı and 14-3-3ǅ rapidly shuttle in and out of the nucleus through active transport. 14-
3-3ı had a 1.7x higher nuclear export rate constant than 14-3-3ǅ, whereas import 
rate constants were equal. Therefore, the difference in subcellular distribution 
between 14-3-3ı and 14-3-3ǅ appeared to be caused by the more efficient export of 
14-3-3ı. Treatment of cells with LMB led to an increase in nuclear 14-3-3 levels and 
to a significant decrease of the export rate constants of both 14-3-3ı and 14-3-3ǅ,
suggesting that these proteins are exported at least in part by a Crm1-dependent 
mechanism.
One possible explanation for the different subcellular distributions and export 
rates of 14-3-3ı and 14-3-3ǅ might rely on the finding that nuclear export of 14-3-3 
could be governed by binding partners. In this model, 14-3-3 itself plays no active 
role in nuclear export and is exported out of the nucleus via a `piggy-back' 
mechanism in which the binding partner provides the NES (Brunet et al., 2002). 
Isoform-specific ligand interactions would in this case cause the different subcellular 
distributions of 14-3-3ı and 14-3-3ǅ. 14-3-3 might preferentially bind ligands that are 
rapidly exported from the nucleus. This model, however, does not explain why 14-3-
3 is required for the nuclear export of some binding partners (Wang and Yang, 2001; 
Brunet et al., 2002).
An alternative model is that sequences in 14-3-3 itself govern nuclear export. 
It has been reported that a putative NES is present in the C-terminus of 14-3-3, in a 
region that also appeared to be involved in ligand binding (Lopez et al., 1999; 
Rittinger et al., 1999). Although this sequence was able to function as NES when 
fused to GFP, a recent study suggests that this region is only involved in ligand 
binding (Brunet et al., 2002). However, one could envisage that the NES of 14-3-3 is 
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(partly) folded into the ligand-binding groove in the absence of a binding partner, 
leading to nuclear retention of unbound 14-3-3. In support of this, the C-terminus 
appears to function in the inhibition of improper 14-3-3-ligand interactions by 
occupying the ligand binding groove (Truong et al., 2002). On ligand binding, the 
NES might be displaced from the groove and become exposed, leading to nuclear 
export through Crm1. In such a model, unbound 14-3-3 would home to the nucleus, 
where after ligand binding its NES is exposed, leading to rapid translocation to the 
cytoplasm. This model would explain why 14-3-3 is required for the nuclear export of 
certain ligands (Brunet et al., 2002). As 14-3-3ı and 14-3-3ǅ both contain an 
identical NES consensus motif (216-DLIMQLLRDNLTLW) in their C-termini, it is 
unlikely that this region is responsible for the difference in subcellular distribution of 
these isoforms. However, the extreme C-terminal region directly flanking the putative 
NES, which might be involved in the structural changes mentioned above, is highly 
divergent and could account for the observed isoform specificity. Clearly, more 
experiments, which are beyond the focus of this analysis, are needed to elucidate the 
molecular mechanisms that underlie the isoform-specific export rates that we have 
measured.
In conclusion, we have shown differences in the subcellular distribution and 
nuclear export kinetics of 14-3-3 proteins, which might be the basis for isoform-
specific biological functions. Our data indicate that one should not think of the 14-3-3 
proteins as static molecules that passively sequester ligands in the cytoplasm. On the 
contrary, 14-3-3 proteins rapidly shuttle in and out of the nucleus, making fast 
responses to signals possible and allowing them to play an active role in changing 
the localisation of binding partners. The rapid nuclear export of 14-3-3ı in particular 
is interesting, as it might reflect a mechanism by which cells can efficiently control 
the nuclear exclusion of proteins involved in cell cycle progression. The high export 
rates of 14-3-3ı are in line with a transient function of this protein in the nucleus 
and with the proposed role of 14-3-3ı in causing rapid DNA damage-induced cell 
cycle arrest through its p53-mediated upregulation and cytoplasmic sequestering of 
Cdc2 (Laronga et al., 2000; Chan et al., 1999; Hermeking et al., 1997). The fact that 
YFP fusion constructs are functional and have the same subcellular distribution as 
endogenous 14-3-3 isoforms creates new and interesting possibilities for future 
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functional studies on 14-3-3 proteins in living cells. Our findings might reflect a 
mechanism that can be the basis for isoform-specific specialisations within multigene 
families in general.
Acknowledgements
  We thank G. Lamers for her help with microscopy and Dr G.P.H. van Heusden 
(Leiden University) for his gift of strain GG1306 and pYES-TRP[BMH2]. The Pan 14-3-
3 antiserum was a generous gift of Dr Paul van der Hoeven (Netherlands Cancer 
Institute, Amsterdam, The Netherlands) and HaCaT cells were a gift of Dr Fusenig 
(DKFZ, Heidelberg, Germany).  
References
Brunet, A., Kanai, F., Stehn, J., Xu, J., Sarbassova, D., Frangioni, J. V., Dalal, S. N., 
      DeCaprio, J. A., Greenberg, M. E. and Yaffe, M. B. (2002). J. Cell Biol.
156, 817-828.
Chan, T. A., Hermeking, H., Lengauer, C., Kinzler, K. W. and Vogelstein, B. (1999). 
Nature 401, 616-620.
Chen, Z., Fu, H., Liu, D., Chang, P. F., Narasimhan, M., Ferl, R., Hasegawa, P. M. and 
 Bressan, R. A. (1994).  Plant J. 6, 729-740.
Craparo, A., Freund, R. and Gustafson, T. A. (1997). J. Biol. Chem. 272, 11663-
 11669.  
Dalal, S. N., Schweitzer, C. M., Gan, J. M. and DeCaprio, J. A. (1999). Mol. Cell. Biol.
19, 4465-4479.
de Vetten, N. C. and Ferl, R. J. (1995). Plant J. 7, 589-601.
Fanger, G. R., Widmann, C., Porter, A. C., Sather, S., Johnson, G. L. and Vaillancourt, 
 R. R. (1998). J. Biol. Chem. 273, 3476-3483.  
Garcia, G. M., Dolfi, F., Russello, M. and Vuori, K. (1999). J. Biol. Chem. 274, 5762-
 5768.  
78
Nucleocytoplasmic shuttling of 14-3-3 
Gietz, R. D., Schiestl, R. H., Willems, A. R. and Woods, R. A. (1995). Yeast 11, 355-
 360.  
Gietz, R. D. and Sugino, A. (1988). Gene 74, 527-534.
Hashiguchi, M., Sobue, K. and Paudel, H. K. (2000). J. Biol. Chem. 275, 25247-
 25254.  
Hermeking, H., Lengauer, C., Polyak, K., He, T. C., Zhang, L., Thiagalingam, S., 
 Kinzler, K. W. and Vogelstein, B. (1997). Mol. Cell. 1, 3-11.
Iwata, N., Yamamoto, H., Sasaki, S., Itoh, F., Suzuki, H., Kikuchi, T., Kaneto, H., Iku, 
 S., Ozeki, I., Karino, Y. et al. (2000). Oncogene 19, 5298-5302.
Jarillo, J. A., Capel, J., Leyva, A., Martinez-Zapater, J. M. and Salinas, J. (1994). Plant 
 Mol. Biol. 25, 693-704.
Jones, D. H. A., Martin, H., Madrazo, J., Robinson, K. A., Nielsen, P., Roseboom, P. 
 H., Patel, Y., Howell, S. A. and Aitken, A. (1995). J. Mol. Biol. 245, 375-384.
Kidou, S., Umeda, M., Kato, A. and Uchimiya, H. (1993). Plant Mol. Biol. 21, 191-
 194.  
Ku, N. O., Liao, J. and Omary, M. B. (1998). EMBO J. 17, 1892-1906.
Kumagai, A. and Dunphy, W. G. (1999). Genes Dev. 13, 1067-1072.
Kumagai, A., Yakowec, P. S. and Dunphy, W. G. (1998). Mol. Biol. Cell 9, 345-354.
Kurz, E. U., Leader, K. B., Kroll, D. J., Clark, M. and Gieseler, F. (2000). J. Biol. 
 Chem. 275, 13948-13954.
Laronga, C., Yang, H. Y., Neal, C. and Lee, M. H. (2000). J. Biol. Chem. 275, 23106-
 23112.  
Leffers, H., Madsen, P., Rasmussen, H. H., Honore, B., Andersen, A. H., Walbum, E., 
 Vandekerckhove, J. and Celis, J. E. (1993). J. Mol. Biol. 231, 982-998.
Lennon, G., Auffray, C., Polymeropoulos, M. and Soares, M. B. (1996). Genomics 33,
 151-152.  
Liu, Y. C., Liu, Y., Elly, C., Yoshida, H., Lipkowitz, S. and Altman, A. (1997). J. Biol. 
 Chem. 272, 9979-9985.
Lopez, G. A., Furnari, B., Mondesert, O. and Russell, P. (1999). Nature 397, 172-
 175.  
Marenholz, I., Zirra, M., Fischer, D. F., Backendorf, C., Ziegler, A. and Mischke, D. 
 (2001). Genome Res. 11, 341-355.
79
Chapter 4 
Markiewicz, E., Wiczynski, G., Rzepecki, R., Kulma, A. and Szopa, J. (1996). Cell Mol. 
 Biol. Lett. 1, 391-415.
Martin, H., Rostas, J., Patel, Y. and Aitken, A. (1994). J. Neurochem. 63, 2259-2265.
Meller, N., Liu, Y. C., Collins, T. L., BonnefoyBerard, N., Baier, G., Isakov, N. and 
 Altman, A. (1996). Mol. Cell. Biol. 16, 5782-5791.
Muslin, A. J., Tanner, J. W., Allen, P. M. and Shaw, A. S. (1996). Cell 84, 889-897.
Pellegrini, G., Dellambra, E., Golisano, O., Martinelli, E., Fantozzi, I., Bondanza, S., 
 Ponzin, D., McKeon, F. and de Luca, M. (2001). Proc. Natl. Acad. Sci. USA 98,
 3156-3161.  
Peng, C. Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S. and Piwnica, W. H. 
 (1997). Science 277, 1501-1505.  
Perego, L. and Berruti, G. (1997). Mol. Reprod. Dev. 47, 370-379.
Petosa, C., Masters, S. C., Bankston, L. A., Pohl, J., Wang, B. C., Fu, H. I. and 
 Liddington, R. C. (1998). J. Biol. Chem. 273, 16305-16310.
Pietromonaco, S. F., Seluja, G. A., Aitken, A. and Elias, L. (1996). Blood Cells Mol. 
 Dis. 22, 225-237.
Rittinger, K., Budman, J., Xu, J., Volinia, S., Cantley, L. C., Smerdon, S. J., Gamblin, 
 S. J. and Yaffe, M. B. (1999). Mol. Cell 4, 153-166.
Roth, D. and Burgoyne, R. D. (1995). FEBS Lett. 374, 77-81.
Roth, D., Morgan, A., Martin, H., Jones, D., Martens, G. J., Aitken, A. and Burgoyne, 
 R. D. (1994). Biochem. J. 301, 305-310.
Sark, M. W., Fischer, D. F., de Meijer, E., van de Putte, P. and Backendorf, C. (1998). 
J. Biol. Chem. 273, 24683-24692.  
Sehnke, P. C., Henry, R., Cline, K. and Ferl, R. J. (2000). Plant Physiol. 122, 235-
 242.  
Subramanian, R. R., Masters, S. C., Zhang, H. and Fu, H. (2001). Exp. Cell Res. 271,
 142-151.  
Tang, S. J., Suen, T. C., McInnes, R. R. and Buchwald, M. (1998). J. Biol. Chem.
273, 25356-25363.
Tien, A. C., Hsei, H. Y. and Chien, C. T. (1999). Mech. Dev. 81, 209-212.
Todd, A., Cossons, N., Aitken, A., Price, G. B. and Zannis-Hadjopoulos, M. (1998). 
Biochemistry 37, 14317-14325.
80
Nucleocytoplasmic shuttling of 14-3-3 
Truong, A. B., Masters, S. C., Yang, H. and Fu, H. (2002). Proteins 49, 321-325.
Tzivion, G. and Avruch, J. (2002). J. Biol. Chem. 277, 3061-3064.
Van Der Hoeven, P. C., van Der Wal, J. C., Ruurs, P., van Dijk, M. C. and van 
 Blitterswijk, J. (2000). Biochem. J. 345, 297-306.
van Hemert, M. J., Steensma, H. Y. and van Heusden, G. P. (2001). Bioessays 23,
 936-946.  
van Heusden, G. P. H., Griffiths, D. J., Ford, J. C., Chin, A. W.-T., Schrader, P. A., 
 Carr, A. M. and Steensma, H. Y. (1995). Eur. J. Biochem. 229, 45-53.
van Heusden, G. P. H., van-der-Zanden, A. L., Ferl, R. J. and Steensma, H. Y. 
(1996). FEBS Lett. 391, 252-256.
van Zeijl, M. J., Testerink, C., Kijne, J. W. and Wanga, M. (2000). FEBS Lett. 473,
 292-296.  
Wakui, H., Wright, A. P., Gustafsson, J. and Zilliacus, J. (1997). J. Biol. Chem. 272,
 8153-8156.  
Wang, A. H. and Yang, X. J. (2001). Mol. Cell. Biol. 21, 5992-6005.
Yaffe, M. B. (2002). FEBS Lett. 513, 53-57.
Zhang, S. H., Kobayashi, R., Graves, P. R., Piwnica-Worms, H. and Tonks, N. K. 
 (1997). J. Biol. Chem. 272, 27281-27287.
Zonneveld, B. J. M. (1986). J. Microbiol. Methods 4, 287-291. 
81
Chapter 4 
82
Chapter 5 
Radiation response and cell cycle regulation of p53 
rescued malignant keratinocytes
Exp Cell Res. 2005 Oct 15;310(1):237-47.
Maarten Niemantsverdriet, Wim Jongmans and Claude Backendorf 
83
Chapter 5 
Abstract
Mutations in the tumor suppressor gene p53 were found in more than 90% of 
all human squamous cell carcinomas (SCC). To study the function of p53 in a 
keratinocyte background, a tetracycline-controlled p53 transgene was introduced into 
a human SCC cell line (SCC15), lacking endogenous p53. Conditional expression of 
wild-type p53 protein upon withdrawal of tetracycline was accompanied with 
increased expression of p21WAF1/Cip1 resulting in reduced cell proliferation. Flow-
cytometric analysis revealed that these cells were transiently arrested in the G1/S 
phase of the cell cycle. However, when SCC15 cells expressing p53 were exposed to 
ionizing radiation (IR), a clear shift from a G1/S to a G2/M cell cycle arrest was 
observed. This effect was greatly depending on the presence of wild-type p53, as it 
was not observed to the same extent in SCC15 cells lacking p53. Unexpectedly, the 
p53 and IR dependent G2/M cell cycle arrest in the keratinocyte background was not 
depending on increased expression or stabilization of 14-3-3ı, a p53 regulated 
effector of G2/M progression in colorectal cancer cells. In keratinocytes, 14-3-3ı
(stratifin) is involved in terminal differentiation and its cell cycle function in this cell 
type might diverge from the one it fulfils in other cellular backgrounds.
Keywords:  TP53, 14-3-3ı, stratifin, p21WAF1/Cip1, cell-cycle checkpoint, DNA damage, 
keratinocyte, ionizing radiation 
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Introduction
 Mutations in the p53 tumor suppressor gene are found in more than 50% of 
human epithelial cancers (Hainaut et al., 1997), resulting in either lack of expression, 
expression of a "loss of function" protein, or increased expression of a mutant p53 
protein that can act as a “gain of function” oncoprotein (Dittmer et al., 1993). P53 
appears to be especially important in protecting keratinocytes from malignant 
transformation, since p53 mutations have been found in more than 90% of 
squamous cell carcinomas (SCC), which are derived from the keratinocyte lineage 
(Leffell, 2000). The cell cycle regulatory function of p53 is believed to maintain 
genomic stability following cellular stress and loss of this function promotes 
malignant transformation (Lane, 1992). The p53 protein is a sequence-specific 
transcriptional activator of several genes, including the p21WAF1/Cip1 and the 14-3-3ı
genes, which are involved in the negative regulation of cell cycle progression in 
response to radiation or other types of cellular stress (Hermeking et al., 1997; 
Jongmans & Hall, 1999). The p21WAF1/Cip1 protein plays an essential role in p53-
mediated G1/S cell cycle arrest by acting as an inhibitor of G1 cyclin-dependent 
kinases (Harper et al., 1993). The findings that ectopic expression of p21WAF1/Cip1
results in G1/S arrest in several cell types (Harper et al., 1995; Medema et al., 1995; 
Qin & Ng, 2001) and that p21WAF1/Cip1 deficient cells fail to arrest in G1/S after DNA 
damage (Maeda et al., 2002) argue that the G1/S arrest observed in cells expressing 
wild-type p53 is a direct result of induction of p21WAF1/Cip1. In colorectal cancer cells, 
the 14-3-3ı protein contributes to p53-mediated G2/M cell cycle arrest by inhibiting 
the activation of the G2-cyclin-dependent kinase cdc2 (Chan et al., 1999; Hermeking 
et al., 1997). HCT116 cells overexpressing exogenous 14-3-3ı arrest in G2. In 
response to ionizing radiation (IR) 14-3-3ı is induced in several colorectal cancer cell 
lines in a p53-dependent fashion, and ectopic expression of p53 in HCT116 cells 
results in an 18 fold induction of 14-3-3ı (Hermeking et al., 1997). 14-3-3ı deficient 
HCT116 cells fail to sequester the cdc2-cyclinB1 complex in the cytoplasm after DNA 
damage. After treatment with adriamycin these cells initially arrest in G2 phase, but 
are unable to maintain cell-cycle arrest and die as they enter mitosis by a process 
85
Chapter 5 
called mitotic catastrophe (Chan et al., 1999). In contrast, 14-3-3ı was shown to 
play a positive role in IGF-I receptor induced cell proliferation in the human breast 
cancer cell line MCF7 (Zhang et al., 2004). Expression of 14-3-3ı is highly cell-type 
specific, in fact 14-3-3ı was originally described as the epithelial cell specific protein 
stratifin (Leffers et al., 1993). Accordingly, 14-3-3ı is not expressed in either 
exponentially growing or Ǆ-irradiated human diploid fibroblasts or human endothelial 
cells (Hermeking et al., 1997). In human epidermal keratinocytes 14-3-3ı is 
expressed at low levels in basal cells, at high levels at the moment of commitment to 
terminal differentiation and again at low levels at later stages of differentiation 
(Dellambra et al., 2000). Keratinocytes arise from stem cells in the basal layer and 
move upwards towards the skin’s periphery as they differentiate and give rise to the 
various layers of the epidermis (Alonso & Fuchs, 2003; Roop, 1995). Down-
modulation of 14-3-3ı forces primary human keratinocytes into the stem cell 
compartment, allowing them to escape from replicative senescence and to become 
immortal (Dellambra et al., 2000).
 In order to determine the role of p53 and the involvement of 14-3-3ı and 
p21WAF1/Cip1 in the regulation of cell cycle progression in keratinocytes, we used the 
human squamous cell carcinoma cell line SCC15 (Rheinwald & Beckett, 1980), which 
does not express endogenous p53 protein (Burns, 1993; Min et al., 1994). 
Conditional expression of wild-type p53 protein in SCC15 cells resulted in 
transactivation of the p21WAF1/Cip1 gene and a transient arrest of the cells in the G1/S 
phase of the cell cycle. Conversely, both wild-type p53 expression and exposure to 
ionizing radiation (IR) were required to efficiently arrest cells in G2/M. In contrast to 
the findings in colorectal cancer cell lines, this G2/M cell cycle arrest was not 
depending on up-regulation or stabilization of 14-3-3ı.
Materials and methods 
Cell culture 
 The SCC15 cell line (generously supplied by Dr. Jim Rheinwald, Cambridge, MA) 
was derived from a squamous carcinoma of the tongue and grown in standard 
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medium (calcium concentration 1.4 mM) containing DMEM and Ham's F12 
(Gibco/BRL) in a 3:1 ratio, supplemented with 5% bovine calf serum (Hyclone) and 
0.4 Pg/ml hydrocortisone (Sigma) (Rheinwald & Beckett, 1980). For tetracycline-
regulated gene induction experiments Tet-system-approved fetal bovine serum 
(Clontech) was used (Tet-free medium). SCC15 cell lines and derivatives were 
cultured in a humidified incubator at 8% CO2 and 37ºC unless indicated differently. 
Cells were irradiated with X-rays using an Andrex SMART-225 device. MG132 was 
purchased from Calbiochem® and used as indicated. The retroviral packaging cell 
line Phoenix (a gift from Dr. G. Nolan, Stanford) was maintained at 5% CO2 and 37ºC
in DMEM supplemented with 10% bovine calf serum (Nolan & Shatzman, 1998). 
Vectors
 The pTEV retroviral vector used in this study was based on the self-inactivating 
SFGtcLucITE1 retroviral vector (Lindemann et al., 1997). 147 bp enhancer sequences 
in the 3' LTR of this retroviral vector have been deleted to decrease basal LTR-
mediated gene transcription when the retroviral vector is integrated in the genome of 
the target cells. The pTEV1 retroviral vector was created by replacing the NcoI-SacII 
(containing the luciferase and tTA genes) by a fragment harbouring a T7 promoter 
sequence followed by multiple unique cloning sites (NcoI-MluI-BamHI-NotI-ClaI-
SacII). To obtain pTEV2, the NcoI site from pTEV1 was deleted. Genes inserted into 
the unique multiple cloning sites of the pTEV retroviral vectors are transcriptionally 
controlled by the CMV promoter that contains a binding site for the tetracycline-
responsive transactivator (tTA). To create pTEVp53, the p53 gene derived from 
pC53-SN3 (Baker et al., 1990) was cloned as a BamHI fragment into pTEV2. The 
control pTEVLuc retroviral vector was obtained by introducing the NcoI-BamHI 
fragment from the SFGtcLucITE1 into the NcoI-BamHI sites of pTEV1. 
The tetracycline-responsive transactivator (tTA) was expressed from pPurTet-Off. 
This plasmid was derived from pRetro-off (Clontech) by replacing the Neo gene by 
the puromycin-N-acetyl-transferase (pac) selection marker. 
 The Luciferase reporter plasmid p21Luc was constructed by insertion of the 
human p21WAF1/Cip1 promoter derived from WWP-Luc (el-Deiry et al., 1993) in front of 
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the luciferase gene of the pGL3-basic plasmid (Promega). The pRSV-p53V143A and 
pRSV-p53wt expression vectors were constructed by inserting the BamHI fragment 
from respectively pC53-SCX3 and pC53-SN3 (Baker et al., 1990) into the unique 
BamHI site of the expression vector pRSV-H2O (gift from Dr. R. Offringa, Leiden).  
Transient transfections 
Cells grown to 80-90% confluence on 5 cm dishes were transiently transfected 
by using the liposome transfection reagent DOTAP (N-[1-(2,3-Dioleoyloxy)propyl]-
N,N,N-trimethylammonium methyl-sulfate) (Roche). 5 Pg of luciferase reporter 
plasmid or a mixture of 5 Pg of luciferase reporter plasmid and 0.5 Pg of RSV-driven 
expression vector were added to 1 ml of calcium-free DMEM. 25 Pg DOTAP was 
added gently and the mixture was incubated for 20 minutes at room temperature. 
Cells washed twice with phosphate-buffered saline (PBS) were supplied with the 
DNA-DOTAP mixture and incubated for 2 hours at 37ºC with occasional rocking of the 
culture dishes. Subsequently, the cells were washed once with PBS and fresh 
standard medium was added. 24 hours after transfection the cells were rinsed with 
cold PBS and collected by scraping in 500 Pl PBS. The cells were resuspended and 
sonicated in 150 Pl cell lysis buffer (Promega). Following centrifugation, the 
luciferase activity of the cleared supernatant was determined in the presence of 
luciferin (Promega) and expressed as relative light units/ǋg protein. 
Retrovirus-mediated Infections 
 Retroviral vectors were transiently transfected into the amphotropic Phoenix 
packaging cell line as described by Dr. G. Nolan 
(http://www.stanford.edu/group/nolan). Transiently produced retroviruses were 
collected after 48 hours, filtered (0.45 Pm; Sarstedt) and added to SCC15 cells in the 
presence of 5 Pg/ml polybrene. SCC15 cell lines in which the expression of the gene 
of interest can be regulated by the tetracycline-responsive transactivator (tTA) were 
established in two steps. First, pPurTet-Off containing the tetracycline-responsive 
transactivator (tTA) was introduced into SCC15 cells by retroviral transduction. After 
24 hours incubation at 32ºC medium was replaced by fresh standard medium and the 
temperature increased to 37ºC. After another 24 hours resistant clones were selected 
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using 1 Pg/ml puromycine. After 2 weeks the puromycine-resistant SCC15 clones 
were pooled and grown for 24 hours in the presence of tetracycline (2Pg/ml).
Infection with pTEV retroviruses was then performed for 24 hours at 32ºC, as 
described above. Individual clones were isolated by dilution cloning and were grown 
in standard medium containing 1 Pg/ml puromycine and 2 Pg/ml tetracycline at 37ºC
and 8 % CO2.
Cell-cycle analysis 
Non-confluent growing cells were trypsinized, washed in PBS, resuspended in 
Hanks’ balanced salt solution buffer (Gibco) and stored at 4ºC in 55% ethanol. Before 
analysis with a FACScalibur flow-cytometer (Becton Dickinson) cells were pelleted, 
resuspended in 1 ml of PBS solution and treated with RNase A (100ǋg/ml) for 40 min 
at 37ºC and with propidium iodide (30ǋg/ml) for 15 min at room temperature.  The 
percentage of cells in various cell cycle phases was determined by DNA histogram 
analysis of at least 10.000 sorted cells using WinMDI 2.8 software. Results presented 
in figures 2 and 4 are based on two independent experiments with similar results. 
Protein isolation and immunoblotting 
Cells grown on 5 cm dishes were washed in PBS and lysed directly on the 
dishes in cold sample buffer (60 mM TRIS pH 6.8, 10 % glycerol, 2 % SDS, 2 % ß-
mercaptoethanol, 0.003 % bromophenol blue) and subsequently sheared by passing 
several times through a 29 gauge needle. Sample solutions were boiled for 5 minutes 
and loaded on a SDS polyacrylamide gel. After staining the gel with Coomassie 
brilliant blue and scanning, equal loading was checked by using the Quantity One-
4.2.1 (Biorad) program. Adjusted volumes of sample were separated alongside 
Rainbow marker proteins (Amersham) or Cruz MarkerTM (Santa Cruz Biotechnology) 
using a mini-gel system and transferred to a nitrocellulose membrane using a semi-
dry blotting procedure or to a PVDF membrane (Hybond-P Amersham) using the Mini 
Protean 3 system (Biorad). Blots were incubated with antibodies against p21(F-5), 
14-3-3ı (N-14) or p53(DO-1) (all from Santa Cruz Biotechnology) and detected by 
the enhanced chemiluminescence detection system (ECL, Amersham) using donkey 
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anti-Goat IgG-HRP for 14-3-3ı or donkey anti-Mouse IgG-HRP for p21 and p53 
(Santa Cruz Biotechnology). 
RNA analysis 
Total RNA was isolated from cells grown to 90% confluence by direct lysis on 
the culture dishes using TRIzol reagent (Invitrogen®) according to the 
manufacturer’s instructions. Equal amounts (20Pg) of total RNA were separated on a 
1% denaturing agarose gel and transferred to a Genescreen membrane (Biotech 
Systems Dupont, Boston, USA). The Northern blot was hybridized with 32P-dCTP
labeled probes as described (Belt et al., 1989). The p53-specific cDNA probe was 
derived from the pC53-SN3 vector excised with BamHI (Baker et al., 1990). The 
p21WAF1/Cip1 specific cDNA probe was generously provided by Dr. M. Ozturk 
(INSERM). The 14-3-3ı specific probe was made by PCR from a keratinocyte cDNA 
library  by using primers: 5’-CCGATGGATCCATGGAGAGAGCCAGTCTGATC and 5’-
CTATGGATCCTCAGCTCTGGGGCTCCTG and was checked by sequencing. Expression 
levels were quantified using the Quantity One-4.2.1 (Biorad) program and expression 
of p53, 14-3-3ı  and p21WAF1/Cip1 was normalized for the level of GAPDH in the same 
samples.
RT-PCR
RNA samples were treated with 20 Units of RNase-free DNaseI (Roche) for 30 
minutes at room temperature and phenol:chloroform extracted. Total RNA was 
reverse-transcribed with Super-RT (SphaeroQ) using random hexamer primers 
(Amersham Pharmacia Biotech). PCR was performed for 30 (Pac, GAPDH, 14-3-3ı,
p53, fig.1) or 35 (p21WAF1/Cip1 and p53, fig.6) cycles, with 20 pmol of gene-specific
primers, 1.5mM MgCl2 and 1.25 Units of Amplitaq Gold TM (Roche).
The following unique primer sets were used: pTEV encoded p53 mRNA: 5'-
TAATACGACTCACTATAGG-3' and 5'-CTTCCACTCGGATAAGATGC-3’; puromycin-N-
acetyl-transferase: 5'-TTCGAATTCAGCTTACCATGACCGAGTA-3' and 5'-
AAAGCCGGCTCAATTGTTTTACGCGGCCCG-3'; GAPDH: 5’- 
CGGAGTCAACGGATTTGGTCGTAT and 5’-AGCCTTCTCCATGGTGGTGAAGAC; 
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p21WAF1/Cip1: 5’-GTGGACCTGTCACTGTCTTGTAC and 5’-CTTCCTCTTGGAGAAGATCAGC 
(Wedemeyer et al., 2000); 14-3-3ı 5’-GTCCGGCATTGGTCCCAG and 5’-
GTCCCCGGCCTCCTTGAT. PCR products were visualized on a 1.5% agarose gel. 
Determination of p53 sequences in various transgenic SCC15 
clones
The transgenic clones  SCC15TEVp53-11, SCC15TEVp53-19 and  
SCC15TEVp53-46 were  induced in Tet-free medium and RNA was isolated using the 
TRIzol method. RT-reactions were performed as described above. The p53 coding 
sequences were amplified as two overlapping fragments. After a 1min hot start at 
940C, PCR was carried out for 35 cycles (20 sec, 940C; 30 sec, 500C; 1 min, 720C)
and followed by final elongation at 720C for 5 minutes. Primers used  for the N-
terminal fragment were:  5’-TAATACGACTCACTATAGG and 5’-
CTTCCACTCGGATAAGATGC and for the C-terminal fragment: 5’- 
CTTGTTCAGTGGAGCCCCG and 5’-GTCTGTGACTTGCACGTACTCC. All PCR products 
were sequenced in two directions and compared to the p53 wild-type sequence  
(NCBI file: X02469). 
Results 
Isolation of tetracycline-regulated p53 transgenic SCC15 cells
 To investigate the effect of wild-type (wt) p53 protein expression on the 
behaviour of human keratinocytes, we used the cell line SCC15, which does not 
express endogenous p53 protein (Burns, 1993; Min et al., 1994). We first examined 
the effect of transient co-transfection of p53 on the transactivation of the p21WAF1/Cip1
promoter in SCC15 cells. Expression of wild-type p53 transactivated the reporter 
construct p21Luc in SCC15 cells. In contrast, no transactivation of this reporter 
construct was seen by co-transfecting mutant p53V143A (data not shown). 
 Having established that ectopically expressed wt p53 is active in SCC15 cells, we 
generated p53 transgenic SCC15 clones in which p53 gene expression is regulated by 
the tetracycline-responsive transactivator (tTA) (see Materials & Methods). Upon 
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withdrawal of tetracycline for 3 days, seven out of forty-four individual SCC15 clones 
(Fig. 1A) were found to express the p53 gene from the pTEVp53. RT-PCR analysis 
was performed with a unique primerset that discriminates between the pTEV-
encoded and endogenous p53 mRNA. Induced levels of p53 mRNA were detected in 
most of the SCC15 cells already 1 day after withdrawal of tetracycline (data not 
shown). However, maximal levels of expression were reached after 3 days (Fig. 1A). 
Marked differences between the levels of basal and induced p53 mRNA expression 
were observed in six of the seven isolated SCC15 clones, with the SCC15TEVp53-19 
and SCC15TEVp53-46 clones showing the lowest levels of both basal and induced 
p53 mRNA. Only clone SCC15TEVp53-44 showed similar levels of p53 mRNA in the 
induced and uninduced states. Identical conclusions could be drawn from Northern 
blot analysis (data not shown). All clones, except SCC15TEVp53-44, expressed p53 
protein upon withdrawal of tetracycline for 3 days (Fig. 1B). Sequence analysis of 
various transgenes established that clones SCC15TEVp53-19 and SCC15TEVp53-46 
expressed wild-type p53, whereas clone SCC15TEVp53-11 contained a glutamic acid 
to lysine substitution at position 286 of the p53 protein. The wild-type clones 
SCC15TEVp53-19 and SCC15TEVp53-46 showed a clear transactivation of the 
reporter plasmid p21Luc (Fig. 1C) whereas no transactivation was observed in 
SCC15TEVp53-11 and  in SCC15TEVp53-44. The lack of transactivation of the p21Luc 
reporter plasmid, combined with the higher basal p53 gene expression levels, 
strongly suggests that the p53 transgene has also become mutated in all other 
clones, similar to the situation in SCC15TEVp53-11. 
 As a control, puromycine resistant SCC15 cells were also infected with 
retroviruses containing a tTA-regulated luciferase gene (pTEVLuc). In three clones 
displaying low levels of luciferase activities in the presence of tetracycline, increased 
luciferase activities were measured upon withdrawal of tetracycline during 3 days. 
One of these three clones, SCC15TEVLuc-1 that was further analyzed, showed no 
expression of p53 upon withdrawal of tetracycline as expected (Fig. 1A). 
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Figure. 1. Isolation of SCC15 clones expressing functional Tet-regulated p53. (A) RT-PCR analysis of 
p53 or Pac (internal control) mRNA, isolated from various SCC15 clones grown for 3 days in medium 
with or without tetracycline. (B) Immunoblot analysis of induced (-Tet) and uninduced (+Tet) p53 
protein levels in SCC15 clones. (C) Transactivation of the p53-responsive p21WAF1/Cip1 promoter in 
SCC15 clones expressing Tet-regulated p53. SCC15 cells grown for 2 days in medium with or without 
tetracycline were transiently transfected with the p21WAF1/Cip1 luciferase reporter construct and cell 
extracts were prepared 24 hours hereafter. Results are represented as the ratio in luciferase activity 
between –Tet and +Tet cultures. (D) Growth curves of SCC15TEVp53-19, SCC15TEVp53-46 and 
SCC15TEVp53-11 cells grown in medium with (open symbols) or without tetracycline (closed symbols). 
Microscope images of day 6 cultures (+/- Tet) are shown. 
Suppression of cell growth following p53 expression in 
transgenic SCC15 cells
 Examination of the growth curves of p53 induced (-Tet) and uninduced (+ Tet) 
SCC15TEVp53-19, SCC15TEVp53-46 and SCC15TEVp53-11 cells revealed a 
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significant difference in cell growth between the two states in the SCC15TEVp53-19 
and SCC15TEVp53-46 cells (Fig. 1D). The uninduced SCC15TEVp53-19 and 
SCC15TEVp53-46 cells continued to grow with a doubling time of approximately 48 
h, whereas the p53 expressing cells showed a substantial reduction in cell growth. In 
contrast, no difference in cell growth was found between the two states in the 
mutant SCC15TEVp53-11 cells (Fig. 1D), indicating that reduced cell growth is due to 
the expression of active wild-type p53 protein. SCC15TEVp53-19 and SCC15TEVp53-
46 cells showed a significantly lower confluence after p53 induction (Fig. 1D, - Tet, 
right panel) as compared to the uninduced state (Fig. 1D, + Tet, left panel). In 
contrast, for the mutant SCC15TEVp53-11 clone, the confluence of induced (Fig. 1D, 
- Tet, right panel) and uninduced (Fig. 1D, + Tet, left panel) cells was very similar. 
DNA histogram analysis showed that S-phase percentages of SCC15TEVp53-19 cells 
were halved from 16% to 8% within 2 days following p53 induction (Fig. 2). During 
the same time the percentage of cells in G1 was increased from 60% to 68% and no 
changes in G2/M were noticed in SCC15TEVp53-19 cells following p53 induction. In 
contrast, the relative percentages of G1, S and G2 phases in SCC15TEVLuc-1 cells 
were not changed significantly after 2 days following tetracycline withdrawal (Fig. 2). 
 The p53 protein controls the expression of the p21WAF1/Cip1 gene, which is involved 
in cell cycle regulation. Therefore, we analyzed p21WAF1/Cip1 RNA expression in 
SCC15TEVp53-19 and SCC15TEVLuc-1 cell lines (Fig. 3). Uninduced SCC15TEVp53-
19 cells showed relatively low levels of p21WAF1/Cip1 mRNA, as was also seen in the 
SCC15TEVLuc-1 cells. However, a strong increase in p21WAF1/Cip1 mRNA levels was 
observed in SCC15TEVp53-19 cells following p53 induction. These p53 induced 
changes in p21WAF1/Cip1 gene transactivation were reflected at the cellular level by a 
decrease in S-phase, an increase in G1 cells and reduced proliferation (Figs. 1D and 
2).
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Figure 2.  DNA histogram analysis of SCC15TEVp53-19 cells and SCC15TEVLuc-1 cells grown for 2 
days in medium with (+Tet) or without (-Tet) tetracycline. The percentages of cells at G1-S, S and G2-M 
are indicated.  
Figure 3. Analysis of p53, p21WAF1/Cip1, 14-3-3ı and GAPDH mRNA levels following a 2 day withdrawal 
of tetracycline in either SCC15TEVp53-19 or SCC15TEVLuc-1 (control) cells. When indicated cells were 
additionally exposed to 6 Gy of ionizing radiation at day 1. The indicated relative expression levels were 
normalized for GAPDH (internal control). 
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Ionizing radiation (IR) induces p53-mediated G2/M cell cycle 
arrest in transgenic SCC15 cells
 SCC15TEVp53-19 and SCC15TEVp53-11 cells were grown in the presence or 
absence of tetracycline and subsequently subjected to ionizing radiation (IR) or 
mock-irradiated. In unirradiated SCC15TEVp53-19 cells, p53 induction resulted in an 
increase of G1 and a decrease in S-phase cells (Fig. 4, panel A) in accordance with 
the results presented in figure 2. Irradiation of uninduced SCC15TEVp53-19 cells 
(+Tet) resulted in a reduction of G1 cells and a moderate increase (16 to 23%) of G2 
cells after a 6 Gy dose (Fig. 4, compare +Tet samples in panels A and B). 
Conversely, when p53 expressing SCC15TEVp53-19 cells (-Tet) were treated with 
ionizing radiation a more prominent arrest in G2/M was observed. After a dose of 6 
Gy the percentage of G2 cells doubled, reaching 34% of the total cell population. 
(Fig. 4, compare -Tet samples in panels A and B).   
 Expression of mutant p53 in SCC15TEVp53-11 did not significantly affect the 
percentage of G2 cells after the same dose of ionizing radiation (Fig. 4, panel D, 
compare +Tet and -Tet), indicating that IR induced G2/M arrest is greatly depending 
on the expression of active wild-type p53.  
 This view is further accentuated by the results of Fig. 4, panel C: after a dose of 
10 Gy induction of wild-type p53 increased the fraction of G2 cells from 38% to 56%. 
Interestingly, at this high dose a pre-G1 peek appeared in SCC15TEVp53-19 cells, 
which is an indication of apoptosis. This pre-G1 peak was less pronounced in p53 
expressing cells (-Tet) than in uninduced cells (+Tet), suggesting that in the 
presence of wild-type p53 G2/M cell cycle arrest might be favored upon induction of 
apoptosis.
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Figure 4.  DNA histogram analysis of SCC15TEVp53-19 cells (A,B,C) and SCC15TEVp53-11 cells (D) 
grown for 2 (A,B,D) or 3 (C) days in +Tet or –Tet medium. When indicated, cultures were exposed to 6 
(B,D) or 10 (C) Gy of ionizing radiation at day 1. 
14-3-3ı is not induced or stabilized by p53 in transgenic SCC15 
cells
 The p53 protein is known to transcriptionally control the expression of the 14-3-3ı
gene. Colorectal cancer cells expressing exogenous p53 showed a significant 
induction (18 fold) of 14-3-3ı as compared to the same cells lacking p53, and 
overexpression of the 14-3-3ı gene in colorectal cancer cells resulted in an 
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accumulation of cells in the G2 phase of the cell cycle (Hermeking et al., 1997). A 
Northern blot analysis of total RNA isolated from induced SCC15TEVp53-19 cells (-
Tet), either exposed to IR or mock-irradiated, displayed a significant increase in 
p21WAF1/Cip1 mRNA levels when compared to uninduced SCC15TEVp53-19 cells (Fig. 
3). In contrast to what was reported for colorectal cancer cells (Hermeking et al., 
1997), no significant (only 1.4 fold) increase of 14-3-3ı mRNA was observed after 
induction of wt p53 in the SCC15TEVp53-19 keratinocytes (Fig. 3). In order to make 
sure that the absence of 14-3-3ı induction is not due to too high levels of wt p53, 
we also analyzed the effect of intermediate levels of p53. When reducing p53 gene 
expression levels by adding increasing concentrations of tetracycline to the medium, 
the levels of p21WAF1/Cip1 mRNA followed the levels of p53 mRNA and decreased in a 
similar way (Fig. 5). However, also under these conditions, no significant change in 
the expression of 14-3-3ı was observed (Fig. 5). 
  14-3-3ı is one of seven highly homologous 14-3-3 genes expressed in human cells 
(van Hemert et al., 2001; Yaffe, 2002). To exclude the possibility that the results 
obtained with Northern blot analysis are due to cross-hybridization of the 14-3-3ı
probe with mRNA from other genes, the results of the Northern blot analysis were 
verified by RT-PCR analysis using a unique primerset for 14-3-3ı (Fig. 6). Whereas 
RT-PCR analysis showed an increase in the p21WAF1/Cip1 level of RNA isolated from p53 
expressing SCC15TEVp53-19 cells, no significant change in the expression level of 
14-3-3ı was observed, neither in cells exposed to 10 Gy of IR nor in mock-irradiated 
cells (Fig. 6). RNA from fibroblasts, which do not express 14-3-3ı, was included as a 
negative control and the identity of the 14-3-3ı RT-PCR products, obtained from the 
transgenic SCC15 cells, was confirmed by DNA sequencing.  
 Apparently, 14-3-3ı is constitutively expressed in SCC15 cells but nevertheless, an 
efficient G2/M cell cycle arrest was only observed in the p53-expressing 
SCC15TEVp53-19 cells following exposure to IR, suggesting that, if 14-3-3ı is
involved in G2/M arrest in keratinocytes, it might be regulated at the protein level 
rather than at the mRNA level. Protein levels of both 14-3-3ı and p21WAF1/Cip1 can be 
regulated by the ubiquitin-proteasome pathway (Cayrol & Ducommun, 1998; Urano 
et al., 2002). 
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Figure 5. Impact of p53 expression levels on p21WAF1/Cip1 and 14-3-3ı mRNA expression: RNA was 
isolated from SCC15TEVp53-19 or SCC15TEVLuc-1 cultures grown for 2 days in the presence of the 
indicated amounts of tetracycline. The indicated relative expression levels were normalized for GAPDH 
(internal control). 
Figure 6.  RT-PCR analysis of Tet-regulated p53, p21WAF1/Cip1, 14-3-3V and GAPDH (control) mRNA 
levels in SCC15TEVp53-19 cells exposed to 10 Gy of IR or mock irradiated. Cells were cultured in –Tet 
medium and subsequently changed to +Tet or kept in -Tet medium. Irradiation (when indicated) was 
performed 24 hours later and at the indicated time points hereafter RNA was isolated. Human fibroblast 
RNA was used as a negative control for 14-3-3ı expression. 
 In figure 7 we have analyzed possible changes in 14-3-3ı (and p21WAF1/Cip1)
protein levels after p53 induction and/or treatment with ionizing radiation by 
immunoblotting, using an anti-14-3-3ı antibody previously tested for its specificity 
(van Hemert et al., 2004). This analysis did not show any significant differences in 
99
Chapter 5 
14-3-3ı protein levels in induced or uninduced SCC15TEVp53-19 cells, either 
exposed to 10 Gy of IR or not irradiated. Protein levels of p21WAF1/Cip1, on the 
contrary, correlated with the expression of p53 (fig. 7A).
Figure 7.  Immunoblot analysis of (A) Tet-regulated p53, p21WAF1/Cip1 and 14-3-3ı protein expression 
in SCC15TEVp53-19 cells exposed to 10 Gy of IR or mock irradiated. Cells were cultured in –Tet medium 
and subsequently either changed to +Tet or kept in -Tet medium. Irradiation (when indicated) was 
performed 24 hours later and at the indicated time points hereafter whole-cell protein extracts were 
prepared and analyzed by immunoblotting. As a loading control, a section of the gel was stained with 
Coomassie Brilliant Blue (CBB). (B) Effect of the MG132 proteasome inhibitor on p21WAF1/Cip1 and 14-3-
3ı protein levels in SCC15TEVp53-19 cells following (mock-) irradiation in either +Tet or –Tet culture 
medium. Cells  grown for 24 hours in +Tet or –Tet medium were irradiated with 10 Gy of IR (or mock 
irradiated) and treated 20 h hereafter with 20ǋM of MG132 (in DMSO) or mock-treated with DMSO. 4 h 
later whole-cell extracts were prepared and analyzed by Western blotting. 
 In order to exclude a possible involvement of the ubiquitin-proteasome pathway 
on 14-3-3ı protein levels in SCC15TEVp53-19 we treated cells with the proteasome 
inhibitor MG132. Protein levels of p21WAF1/Cip1 were again analyzed as a control. A 
strong increase in p21WAF1/Cip1 protein was observed in SCC15TEVp53-19 cells 
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expressing p53 after proteasome inhibition by MG132 as compared to mock (DMSO) 
treated cells (fig 7B). Even uninduced SCC15TEVp53-19 cells show a visible 
p21WAF1/Cip1 band after MG132 treatment, which is more prominent in irradiated cells, 
indicating p53-independent low level induction of p21WAF1/Cip1 following irradiation. In 
contrast, induced, uninduced, irradiated and unirradiated MG132 treated 
SCC15TEVp53-19 cells all showed similar levels of 14-3-3ı protein as compared to 
mock treated cells (fig. 7B), indicating that in these cells the constitutive levels of 14-
3-3ı have overcome proteasome dependent regulation. 
Discussion
 We have introduced a tetracycline-regulated wt p53 gene into SCC15 cells that 
lack endogenous p53, and examined the effect of wt p53 expression and/or ionizing 
radiation on proliferation, cell cycle regulation and on the conditional expression of 
the p53 target genes, 14-3-3ı and p21WAF1/Cip1. Increased levels of p53 mRNA and 
protein were detected in several SCC15 clones, following withdrawal of tetracycline. 
From the various p53-expressing SCC15 clones that were isolated, only two clones, 
SCC15TEVp53-19 and SCC15TEVp53-46, that had undetectable levels of p53 mRNA 
in the presence of tetracycline, expressed wild-type p53 following tetracycline 
withdrawal, as was concluded from sequencing analysis. Expression of this wild-type 
p53 transgene resulted in increased p21WAF1/Cip1 gene expression and reduced cell 
growth. In SCC15TEVp53-11, the p53 transgene was mutated which resulted in 
substitution of a glutamic acid by a lysine residue at position 286.  
 Residue 286 is located in the DNA binding domain, the region where more than 
90% of all p53 mutations in cancer are found. Substitution of E286 was previously 
detected in several types of cancer (Feki & Irminger-Finger, 2004) and it was 
established that a substitution of E286 constitutes a loss-of-function mutation which 
results in a complete loss of the transactivation capacity (Thukral et al., 1994). Our 
finding that expression of a p53 transgene with an E286 substitution in 
SCC15TEVp53-11 cells did not result in any measurable increase of p21WAF1/Cip1 and 
did not affect the growth properties of SCC15 cells further highlights the functional 
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dependence between expression of wild-type p53 expression, p21WAF1/Cip1
transactivation and the cellular consequences that were observed. 
 In the EJ human bladder carcinoma cell line conditional expression of wild-type 
p53 resulted in irreversible growth arrest in G1 and G2/M, reflecting features of 
cellular senescence (Sugrue et al., 1997). A similar outcome was observed after 
conditional expression of p21WAF1/Cip1 in the same cells (Fang et al., 1999). Analysis of 
the cell cycle distribution in our SCC15TEVp53-19 keratinocyte culture revealed that 
wild-type p53-expressing SCC15 cells were mainly arrested in the G1/S but not in the 
G2/M phase of the cell cycle. Although induced SCC15TEVp53-19 cells displayed 
some features of replicative senescence (e.g. increased cell size and a flatter 
appearance, Fig. 1D), growth curve analysis indicated that the G1/S cell cycle arrest 
monitored by flow cytometric analysis was transient, since the cells continued to 
proliferate albeit at a reduced rate. Since this reduced rate of cell proliferation in p53 
expressing SCC15 cells occurred despite high levels of p21WAF1/Cip1 transcription (Fig. 
3), it follows that p21WAF1/Cip1 is not able to impose a similar prominent cell cycle 
arrest in our cell system as in the bladder carcinoma cell lines discussed above. This 
difference is likely inherent to the use of a keratinocyte background. It has been 
shown by others that high levels of p21WAF1/Cip1 inhibit late stages of keratinocyte 
terminal differentiation (Di Cunto et al., 1998). The down-modulation by proteolytic 
degradation of p21WAF1/Cip1 that occurs at late stages of keratinocyte differentiation 
could underlie the less prominent cell cycle arrest that we have observed. Our 
finding, that a major part of the p53-induced p21WAF1/Cip1 protein is indeed rapidly 
degraded by the proteasome system in SCC15 cells (Fig. 7), is in line with this vision. 
 Following exposure to ionizing radiation a clear shift from a G1/S to a G2/M cell 
cycle arrest was observed in SCC15 cells expressing wt p53. These observations are 
in line with the findings of Flatt et al. (Flatt et al., 1998), who have studied the effect 
of IR on normal human keratinocytes and have also monitored a predominant G2/M 
cell cycle arrest. Our results show that in keratinocytes a combination of both 
ionizing radiation and expression of wt p53 is required to induce an efficient G2/M 
arrest. This increase in G2/M is accompanied by a clear attenuation of the G1/S cell 
cycle arrest (Fig. 4). A similar attenuation has also been observed in normal human 
keratinocytes following IR by Flatt and coworkers (Flatt et al., 1998). In contrast to 
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fibroblasts, where IR results in a complete inhibition of DNA synthesis, human 
keratinocytes continue to cycle at reduced rate and accumulate in G2/M (Flatt et al., 
1998). Our results indicate that X-ray irradiation was not able to further increase 
either p21WAF1/Cip1 transcript (Fig. 6) or protein levels (Fig. 7) in cells expressing wild-
type p53. As these levels are not sufficient for permanent arrest in G1/S (Fig. 1 and 
discussion above), the irradiated cells will progress in the cell cycle until the G2/M 
boundary, where they will arrest. This can be concluded from the p53-dependent 
increase in G2/M phase and the decrease in S-phase both after 6 and 10 Gy X-ray 
exposure (Fig. 4B/C). Such a decrease in S-phase cells is not observed in irradiated 
cells not expressing p53 (Fig. 4A/B, +Tet) or cells expressing mutant p53 (Fig. 4D), 
indicating that in keratinocytes a prominent radiation induced G2/M arrest is 
depending on wt p53 expression. 
 As we have shown that in keratinocytes G2/M cell cycle arrest is both p53 and IR 
dependent it was interesting to look for p53 target genes that would be responsible 
for this outcome. An obvious candidate for such a function is 14-3-3ı (stratifin), 
which was previously shown to play an important role in p53-dependent G2/M cell 
cycle arrest after DNA damage (Hermeking et al., 1997) by sequestering the cdc2-
cyclinB1 complex in the cytoplasm (Chan et al., 1999). The involvement of 14-3-3ı in 
G2/M О cell cycle arrest is often assumed to be a general property of this protein. 
However, experiments that show a direct link between p53 expression, 14-3-3ı
Оinduction and G2/M cell cycle arrest were performed almost exclusively in colorectal 
cancer cell lines. In contrast to the negative role of 14-3-3ı  in cell proliferation in 
human colorectal cancer cells after DNA damage, induction of 14-3-3ı appears to 
play a positive role in IGF-I receptor-induced cell proliferation in MCF-7 breast cancer 
cells (Zhang et al., 2004) or in androgen receptor and epidermal growth factor 
signaling in prostate cells (Huang et al., 2004). In both cell types this function of 14-
3-3ı was p53-independent. 
 In our keratinocyte background we did not observe significant changes in 14-3-
3ı transcript or protein levels following wild-type p53 expression or after irradiation 
with ionizing radiation (Figs. 3, 5, 6 and 7). Instead, in the SCC15 cells 14-3-3ı
appears to be constitutively expressed, as it is in normal keratinocytes (Dellambra et 
103
Chapter 5 
al., 2000). Apparently, the biological function of 14-3-3ı in keratinocytes is 
independent of p53 cell cycle control.
 In human keratinocytes 14-3-3ı is required for clonal evolution, that is the 
transition from stem cells to transit-amplifying cells. Indeed, Dellambra and co-
workers have shown that down-regulation of 14-3-3ı forces primary keratinocytes 
into the stem cell compartment (Dellambra et al., 2000), prevents replicative 
senescence and promotes immortalization of primary human keratinocytes. As 
transit-amplifying cells are still able to proliferate, although with a lower capacity for 
self-renewal and a higher probability of undergoing terminal differentiation, it is 
indeed unlikely that 14-3-3ı expression would result in a permanent cell cycle arrest 
in keratinocytes as it does in colorectal cancer cells (Hermeking et al., 1997). 
Similarly, the skin of keratin 10 null mice displays hyperproliferation of basal cells 
despite highly increased expression levels of 14-3-3ı mRNA and protein (Reichelt & 
Magin, 2002) and in several hyperproliferative human skin diseases high levels of 14-
3-3ı have been recorded. 
 In conclusion, we have generated cell lines that allow investigation on the 
influence external factors like ionizing radiation, either in the presence or absence of 
wild-type p53, in an otherwise genetically identical human keratinocyte background. 
We have shown that expression of wild-type p53 results in decreased cell 
proliferation due to a transient G1/S cell cycle arrest. After ionizing radiation a clear 
shift from a transient G1/S to a more prominent G2/M cell cycle arrest was observed. 
This G2/M arrest depended largely on the expression of wild-type p53, but was not 
mediated by increased expression or stabilization of the 14-3-3ı protein. In 
keratinocytes the biological function of 14-3-3ı appears to reside above all in the 
control of long-term processes such as cell senescence and/or terminal differentiation 
(Dellambra et al., 2000) rather than in the acute inhibition of cell cycle progression 
after DNA damage. 
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TwinGFP, a marker for cell cycle analysis in transiently 
transfected cells
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Abstract
 Green fluorescent protein is widely used as a marker to identify transfected 
cells either by fluorescence microscopy or flow cytometry. However, cell cycle 
analysis  with propidium iodide typically employs ethanol for cell permeabilization. 
During this treatment soluble GFP proteins generally leak out of cells, probably due 
to their small size. We have now significantly improved cellular retention by creating 
an in-frame fusion of two GFP DNA sequences, thus generating a double-sized GFP 
protein (TwinGFP: 57 kD). Permeabilized HeLa cells transfected with pTwinGFP 
showed a strong green fluorescent signal localized throughout the cells, which could 
easily be detected by fluorescence microscopy and flow cytometry in contrast to cells 
transfected with a standard single GFP construct. The experiment indicates that 
protein size constitutes the major determinant for the loss of fluorescence in 
permeabilized cells. As a proof of principle, pTwinGFP was co-transfected with the 
p53 tumor-suppressor gene into HeLa cells, and cells transiently expressing p53 
could be identified and phenotypically characterized by flow cytometry. 
Keywords: GFP duplication; green fluorescent protein; p53; cell permeabilization; 
apoptosis; FACS 
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Introduction
Cell-cycle arrest and apoptosis are routinely studied by flow cytometry 
(Ormerod, 2002). By definition, sustained expression of gene-products inducing 
these regulated cellular processes is not possible, which eliminates the possibility to 
create stable viable cell lines. Conditional expression of this class of genes is a 
possibility but the approach is very labor-intensive and the probability to select 
mutants is very high (Niemantsverdriet et al., 2005). Transient transfections 
constitute an interesting alternative but are often hampered by the low percentage 
of cells that take up DNA during most transfection methods. 
Enhanced green fluorescent (GFP) protein is widely used as transfection 
marker because its fluorescence is independent of other proteins, co-factors or 
substrates and it is expressed as an inert soluble protein throughout the cell (Schmitz 
& Bereiter-Hahn, 2001; Tsien, 1998). Plasmids expressing GFP proteins can be co-
transfected in combination with plasmids expressing proteins involved in cell-cycle 
arrest or apoptosis to identify those cells that have taken up the gene of interest. 
However, protocols for cell-cycle progression or apoptosis studies by flow cytometry 
rely on effective and quantitative measurement of the DNA content by propidium 
iodide staining and require permeabilization of the cells, which is routinely achieved 
with ethanol treatment (Kalejta et al., 1999; Kalejta et al., 1997). Observations in a 
number of laboratories have indicated that the commercially available GFP proteins 
are not retained in the cells after ethanol treatment (Kalejta et al., 1999; Kalejta et 
al., 1997; Kusser & Randall, 2003). To prevent leakage of GFP, cells have been fixed 
with cross-linking agents prior to permeabilization. Several disadvantages have, 
however, been observed using this approach: GFP associated nonspecifically with 
microfilaments (Schmitz & Bereiter-Hahn, 2001), its conformation changed resulting 
in a decrease of brightness (Kusser & Randall, 2003), the cell morphology was 
affected and fixation has also been found to interfere with detection by flow 
cytometry (Kalejta et al., 1997; Kusser & Randall, 2003). Other researchers have 
tagged their GFP with targeting signals that direct the protein to specific cellular 
compartments or induce membrane-anchorage. These adaptations have indeed 
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resulted in the retention of GFP in permeabilized cells (Harvey et al., 2001; Kalejta et 
al., 1999; Kalejta et al., 1997).
If the loss of GFP from permeabilized cells is simply due to its small molecular 
size, then a double-sized GFP protein, created by recombinant gene-duplication, 
which can be expected to have the same properties as the single protein, should 
provide a useful complement to targeted GFP proteins. Here we show that TwinGFP 
has indeed the same cellular localization as the single protein but it is retained in 
ethanol treated cells. Experimental data show that TwinGFP can be used to identify 
and gate transiently transfected cells in flow cytometry, even at low transfection 
efficiency.
Materials and methods 
Plasmids 
pTwinGFP was constructed by ligating the fragment encoding EGFP from 
pEGFP-C1 (Clontech Inc., Palo Alto, CA) digested with SalI and Eco47-III in the 
pEGFP-N1 plasmid (Clontech Inc., Palo Alto, CA) digested with XhoI and Eco47-III. 
Upon expression the resulting fusion consists of two identical EGFP sequences 
separated by a 34 amino acid spacer, derived from parts of the multiple cloning site 
sequences (GLRSRAQASNSAVELKLRILQSTVPRARDPPVAT). pCMV-Neo and pC53-SN3 
(Baker et al., 1990) were generously provided by Dr. B. Vogelstein (Johns Hopkins 
University, Baltimore, MD). Plasmid pcDNAp53 was constructed by inserting a DNA 
fragment containing the complete p53 coding sequence from pC53-SN3 into the 
BamHI site of pcDNA3 (purchased from Invitrogen) in the correct orientation. 
Cell culture, transfection and microscopy 
 HeLa and Saos-2 cells were cultured in DMEM supplemented with 10% Fetal 
Bovine Serum. HeLa cells were grown to 70% confluence on 6 cm dishes, washed 
twice with DMEM and transfected with a total of 5 ȝg plasmid DNA per dish using the 
liposome transfection reagent DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N, N, N-
trimethylammonium methyl-sulfate) (Roche). Saos-2 cells were transfected by using 
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the Amaxa system according to the recommendations of the supplier (Amaxa 
Biosystems). Transfected cells were analyzed with a Zeiss Axiovert 135 microscope, 
equipped for GFP visualization with a DAPI/GFP filter (Zeiss) and for propidium iodide 
plus GFP visualization with a triple-band CFP/YFP/dsRed filter (Omega Optical Inc.). 
The fluorescence of microscopic pictures was quantified by using the imageJ (NIH, 
Bethesda) freeware program. 
Flow cytometry 
 Cells were trypsinized, suspended in PBS containing 10% serum (for trypsine 
inactivation), washed with PBS and resuspended in 300 ȝl PBS, permeabilized by 
adding 700 ȝl cold (-20oC) 100% ethanol and samples were kept at -20oC. Before 
analysis with a FACScalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ), 
cells were pelleted, resuspended in 0.2 ml PBS and treated with RNase A (10 ǋg/ml)
and propidium iodide (10 ǋg/ml for microscopic analysis and 100 ǋg/ml for FACS 
analysis) for 30 min. at room temperature. For each sample 100.000 cells were 
sorted and analyzed using WinMDI 2.8 software.
Results
Because the basic properties of EGFP are very suitable for flow cytometry 
measurements and the protein size might be the major problem when 
permeabilization is required, we constructed pTwinGFP, a plasmid that expresses a 
double sized EGFP protein (Fig. 1 A, see materials and methods for details). After 
transfection of the resulting pTwinGFP plasmid into HeLa cells, green fluorescence 
was readily observed throughout the cells (Fig. 1 B). Phase contrast visualization of 
the same microscopic field showed no differences in morphology between cells 
expressing TwinGFP protein and untransfected cells (Fig. 1 C). 
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Figure 1. Cellular distribution of TwinGFP. (A) Schematic representation of the TwinGFP construct. 
Two identical GFP sequences (GFP1 and GFP2) are separated by a spacer  sequence (hatched). Start 
codons of both GFP sequences (ATG), the stop codon (second GFP), the restriction enzymes used for 
the construction and the amino acid numbering of the two individual GFP sequences are indicated. 
(B) Fluorescence analysis of HeLa cells, 24 hours after transfection with pTwinGFP. (C) Phase 
contrast visualization of the same microscopic field as in (B). 
The intensity and cellular distribution of the fluorescence of TwinGFP was very 
similar to the one found after transfection of the same cells with either pEGFP-C1 or 
pEGFP-N1 (Fig. 2 B). As expected, no fluorescence was observed in HeLa cells 
transfected with the control pCMV-Neo vector (Fig. 2 B). Immunoblot analysis of 
protein extracts derived from pTwinGFP transfected HeLa cells showed that indeed a 
double sized GFP protein was expressed (data not shown).  When HeLa cells 
transfected with pTwinGFP were trypsinized and treated with ethanol, green 
fluorescence was clearly visible, in contrast to cells transfected with pEGFP-C1 or 
pEGFP-N1 (Fig. 2 C). Counterstaining DNA with propidium iodide (PI) (red 
fluorescence) indicated that all cells were indeed permeabilized (Fig. 2 D). After 
permeabilization of pTwinGFP transfected cells, a consistent decrease (approximately 
30%) in the number of fluorescent cells was found (compare the TwinGFP panels in 
Fig. 2B and 2C), indicating that duplication of the GFP reading frame significantly 
deminishes cellular leakage of the protein, but does not prevent it completely.
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Figure 2. TwinGFP is retained in transfected cells after ethanol treatment. HeLa cells were transiently 
transfected with pCMV-Neo, pEGFP-N1, pEGFP-C1 or pTwinGFP. After 24 hours cells were trypsinized, 
suspended in PBS containing 10% serum and one part of the cell suspension was immediately 
photographed either under phase contrast illumination (A) or fluorescence visualization using a 
DAPI/GFP filter (B). A second part of the cell suspension was ethanol-treated at -20ºC, suspended in 
PBS containing RNase A and propidium iodide (see Materials & Methods) and visualized by 
fluorescence microscopy, using either a DAPI/GFP for GFP detection (C) or a triple band 
CFP/YFP/dsRed filter for both GFP (green) and propidium iodide (red) detection (D).
Besides HeLa cells (cervix adenocarcinoma), we have also tested Saos-2 cells 
(osteosarcoma) for improved retention of TwinGFP after EtOH permeabilization. The 
results are very similar to the ones described for the HeLa cells and indicate that also 
in Saos-2 cells a substantial amount of (60-65%) of GFP transfected cells retain 
green fluorescence after EtOH permeabilization, in contrast to pEGFP-N1 and pEGFP-
C1 transfected cells (Fig. 3).
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Figure 3. TwinGFP is retained in ethanol permeabilized Saos-2 cells. Saos-2 cells were transfected 
with pEGFP-N1 (bars 1 & 2), pEGFP-C1 (bars 3 & 4) or pTwinGFP (bars 5 & 6) treated and analyzed 
24 hours later by fluorescence microscopy as described in the legend of figure 2. Cells were 
trypsinized and analyzed immediately (bars 1, 3, 5) or permeabilized by ethanol treatment as 
described in the legend of figure 2 (bars 2, 4, 6). The relative green fluorescence (per cell) was 
determined by using the ImageJ software. The relative fluorescence of the non-permeabilized pEGFP-
N1 and pEGFP-C1 (bars 1 & 3) was set at 100%. 
Having established that the TwinGFP protein is retained efficiently in various 
cell types after ethanol treatment, we analyzed the cell cycle distribution of 
transfected cells by flow cytometry. While cells transfected with pCMV-Neo showed a 
dot-plot pattern that resembled the pattern of untransfected cells (Fig. 4 A, B, left 
panels), cells transfected with pTwinGFP also showed a cell population 
(approximately 38%) with measurable GFP fluorescence levels (Fig. 4 A, B, right 
panels). No effects of TwinGFP on the cell cycle were observed (Fig. 4C, compare left 
and right panels). 
Expression of p53 has been used previously to show the functionality of 
plasmids expressing GFP proteins modified for flow cytometric purposes (Kalejta et 
al., 1997). P53 is a tumor suppressor gene mutated in many human tumors. When 
overexpressed as the wild-type protein in cultured cells, it induces cell cycle arrest or 
apoptosis (Vogelstein et al., 2000).  Apoptotic cells are characterized by extensive 
DNA degradation, which can be identified as a pre-G1 peak in DNA histograms 
obtained by flow-cytometry. (Haupt et al., 1995; Iwashina et al., 1998; Ormerod, 
2002). It was established that HeLa cells transiently transfected with a p53 
expression plasmid show a pre-G1 peak indicating apoptosis (Haupt et al., 1995). 
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Figure 4. TwinGFP can be detected by flow cytometry in ethanol-treated cells. HeLa cells were 
transfected with pCMV-Neo (left column) or pTwinGFP (right column), 24 hours after transfection cells 
were treated with ethanol and DNA was stained with propidium iodide before flow cytometric analysis. 
(A) Bivariate dot-plots showing the distribution of green fluorescence on the y-axis (GFP) versus the 
red fluorescence of propidium iodide staining (representing DNA content) on the x-axis. (B)
Histogram of the distribution of green fluorescence along the y-axis of the respective dot-plots in 
panel A; M1 represents the fraction of cells showing a GFP signal. (C) DNA histograms (red 
fluorescence) corresponding to the cells analyzed in the respective dot-plots in panel A. G1 and G2 
phases of the cell cycle are indicated.  
We co-transfected 4 ȝg pcDNAp53 (pcDNA3 expressing wild type p53) or 
pcDNA3 (empty vector control) (Baker et al., 1990) with 1 ȝg pTwinGFP into HeLa 
cells. 24 hours later, cells were trypsinized, treated with ethanol and the DNA was 
stained with propidium iodide. In a control experiment (Fig. 5 A, B, C), where HeLa 
cells were co-transfected with pcDNA3 and pTwinGFP, less than 5% of the cells 
showed a pre-G1 population.  This value was not significantly influenced by gating 
cells with a low (area R1) or a high (area R2) GFP signal (Fig. 5 B, C, G, open bars). 
Similar background levels were previously found by others in HeLa cells (Haupt et al., 
1995). Cells expressing p53 (Fig. 5 D, E, F) showed a clear increase in apoptotic cells 
which was directly related to the GFP signal. In the population with a low GFP signal, 
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indicative of low p53 expression (area R1), approximately 8% of the cells were 
apoptotic (Fig. 5 E, G, closed bar). In the population with a high GFP signal (area R2) 
the percentage of apoptotic cells increased until 18.0% (Fig. 5 F, G, closed bar). 
Discussion
Because GFP proteins are not retained in ethanol treated cells, we constructed 
plasmid pTwinGFP by creating an in-frame fusion of two EGFP DNA sequences. After 
ethanol treatment, both HeLa and Saos-2 cells transfected with pTwinGFP showed a 
clear green fluorescence, which could be detected by fluorescence microscopy and 
quantified by flow cytometry. No fluorescence was observed in permeabilized cells 
transfected with plasmids expressing single EGFP. Although some decrease in the 
number of fluorescent cells was observed in both cell lines, 60-70% of the cells are 
still clearly positive, indicating that protein size is the major reason for the loss of this 
protein from ethanol treated cells. Apparently by increasing the size of GFP, the twin 
protein is less likely to diffuse out of permeabilized cells. However, as ethanol is also 
a mild fixative, it can not be completely ruled out that TwinGFP is more easily 
immobilized than its single counterpart. It can also not be ruled out that other factors 
might be responsible for the difference in functionality in cytometic experiments 
between single GFP proteins and TwinGFP. In any case, our research demonstrates 
that a significant amount of TwinGFP is retained in ethanol treated cells and 
constitutes as such a useful innovation for cytometric studies.  Hence, TwinGFP can 
be used as a marker to identify cells transiently co-transfected with a given gene of 
interest. As the focus in this type of experiments is generally on the identification of 
the transfected rather than the untransfected cells (which can be studied in a control 
transfection where the gene of interest has been omitted), the loss of some of the 
fluorescence during the permeabilization step (see above) should not constitute a 
major obstacle. That this is indeed the case was shown by the p53 co-transfection 
experiment.
When pTwinGFP was co-transfected with a plasmid expressing p53, an 
increase in apoptotic cells was measured compared to pcDNA3 transfected control 
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cells. More importantly, the percentage of apoptotic cells was higher in cells showing 
a high GFP signal than in cells showing a low GFP signal, indicating a direct 
correlation between the expression level of TwinGFP and the expression level of the 
gene of interest (p53 in our case). This makes TwinGFP a suitable transfection 
marker. The percentage of cells that take up plasmid DNA during transfection varies 
and both transfection method and cell type influence the transfection efficiency. By 
using TwinGFP as a transfection marker in co-transfection experiments, flow 
cytometric measurements can be corrected for low transfection efficiency by sorting 
a large number of cells and selecting those cells that have taken up high amounts of 
plasmid DNA by gating the cells with high green fluorescence. 
Figure 5. TwinGFP fluorescence reflects the expression level of a co-transfected gene (p53).  HeLa 
cells were co-transfected with either 4 ǋg pcDNA3 (A, B, C) or pcDNAp53 (D, E, F) and 1ǋg
pTwinGFP; 24 hours after transfection, both adherent and non-adherent cells were treated with 
ethanol and DNA was stained with propidium iodide before flow cytometric analysis. (A, D) Bivariate 
dot plots representing GFP fluorescence versus DNA content; the gated cell populations R1 (low GFP 
content) and R2 (high GFP content) are indicated. (B, E) DNA histograms of low green fluorescent 
cells (gate R1 in panels A and D respectively); M1 represents the fraction of apoptotic cells (pre-G1 
population). (C, F) Cell cycle distribution of high green fluorescent cells (gate R2); M1 indicates the 
fraction of apoptotic cells (pre-G1 population). Note the extra pre-G1 peak in panel F. (G) Direct 
graphic comparison of apoptotic cell fractions in the gated R1 (low GFP) and R2 (high GFP) cell 
populations after transfection of either wild-type p53 (pcDNAp53) (black bars) or a control plasmid 
(pcDNA3) (white bars). Results are derived from 3 independent experiments. The average background 
level of apoptosis in the HeLa cell cultures (after transfection) is indicated by a dotted line. 
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TO THE EDITOR 
The gene TP73 has been identified as a homologue of tumor suppressor TP53 
and is expressed from 1p36, a region frequently deleted in human cancers (Melino et 
al., 2002). TP73 is expressed from two distinct promoters, which results in TAp73 
and ƩNp73 isoforms. TAp73 isoforms contain a transactivation domain and are able 
to act as transcription factors and transactivate p53 target genes like p21WAF1/Cip1 
and 14-3-3ı. ƩNp73 isoforms lack the transactivation domain and can inhibit the 
function of TAp73 isoforms and p53. TP73 also presents a wide array of C-terminal 
splice variants called Į, ǃ, Ǆ, į, İ and ǅ. The resulting p73 proteins have different 
biological functions and are involved in development, apoptosis, cell-cycle arrest and 
oncogenesis. Several types of leukemia and solid tumors express much higher levels 
and alternative combinations of p73 splice variants compared to the tissue from 
which they originated (Melino et al., 2002; Sahu et al., 2005). Hence, the 
identification of all possible splice variants is essential to fully understand the 
involvement of TP73 in carcinogenic transformation. However, contrasting results 
regarding p73 mRNA expression in haematopoietic malignancies obtained by 
different investigators have been noted (Sahu et al., 2005).
RT-PCR is a simple and easy method that has been frequently used to identify 
C-terminal p73 splice variants expressed in various human cell types and tissues. By 
choosing PCR primers outside the region spliced out, several p73 forms can be 
identified simultaneously (Scaruffi et al., 2000; Zwahlen et al., 2000; Ishimoto et al, 
2002; Tschan et al., 2000). Based on results obtained by this method specific p73 
splice variants have been linked to various forms of leukaemia (Scaruffi et al., 2000; 
Tschan et al., 2000) 
In an effort to further validate this approach, we have tested whether the 
detection of all C-terminal p73 splice variants expressed in a given tissue is 
independent of the total amount of cDNA analysed. For this purpose, we have used 
four different concentrations of cDNA derived from cultured SCC15 cells (human 
squamous cell carcinoma) as template and PCR primers in exons 8 and 14 of p73 
(Zwahlen et al., 2000).
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Unexpectedly, our analysis showed that not all p73 splice variants present in 
the cDNA sample are detected in every PCR reaction. In the PCR reactions with the 
two lowest amounts of SCC15 cDNA, splice variants p73Į, p73Ǆ and p73İ were 
detected (Figure 1a). In the PCR mixture containing the second highest amount of 
cDNA, a p73į band and a lower (221 bp) band appeared whereas p73Į was hardly 
visible (Figure 1a), while in the PCR reaction with the highest amount of cDNA the 
221 bp band was the only band detected (Figure 1a). The identity of splice variants 
was determined by sequencing (Figure 1b, data not shown). Since the smallest C-
terminal splice variant described in almost all p73 research and review articles is 
p73į (Melino et al., 2002; Ishimoto et al, 2002; Tschan et al., 2000) we focused 
specifically on the 221 bp band. Sequence analysis showed that the 221 bp band was 
indeed amplified from a genuine p73 splice variant, where exons 10, 11, 12 and 13 
were spliced out (Figure 1b). The same splice variant was described previously as 
p73ǆ in this journal by Scaruffi et al. A schematic representation of the p73 splice 
variants including the p73ǆ form is presented in Figure 1c. Scaruffi et al. (Scaruffi et 
al., 2000) have suggested a specific role for p73ǆ in the differentiation of acute 
lymphoblastic leukaemia (ALL) based on their finding that the expression of this 
variant is restricted to a small percentage of more differentiated B-cell ALL (This 
p73ǆ splice variant should not be confused for another splice variant first described 
by Ishimoto et al. (Ishimoto et al, 2002), also denominated p73ǆ; this form is 
characterised by alternative termination, has a long exon 13 containing a stop codon 
and encodes a 571-amino-acid protein). Besides, its presence in SCC15 cells, the 
p73ǆ form was also detected in HaCaT (immortal keratinocyte cell line) and HCT116 
(colorectal cancer cell line) cells (Figure 1d). It was not detected in HeLa cells (cervix 
carcinoma cell line) and in cultured primary human cells (keratinocytes and 
fibroblasts), despite the use of high concentrations of cDNA in the PCR reaction. 
Hence, we found expression of p73ǆ in three out of four transformed cell lines 
analysed (Figure 1a and d), but detection of p73ǆ (and other splice variants) 
depended strongly on the concentration of template used.  This indicates that 
extreme care must be taken when making statements on the absence or presence of 
p73 splice variants from results obtained by RT-PCR. Our results demonstrate that 
when shorter splice variants of p73 are present in amplifiable amounts in the PCR 
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mixture, larger splice variants become underrepresented during amplification (Figure
1a). This PCR bias (Shagin, DA et al. Nucleic Acids Res 1999; 27, e23) cannot be 
circumvented by using more sophisticated PCR techniques such as real-time RT-PCR, 
which has the same preference towards the amplification of small splice variants as 
conventional RT-PCR. 
In conclusion, we believe that RT-PCR of different splice variants of p73 can 
be used in a meaningful way for qualitative purposes, provided that care is taken to 
analyse various dilutions of the template cDNA. For quantitative purposes it will be 
imperative to design splice-variant specific primers to produce unique PCR fragments 
that can be quantified by real-time PCR. Only if these precautions are being taken, 
meaningful statements on possible links between specific p73 splice variants and a 
specific carcinogenic phenotype can be made.
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Figure 1. (a) RT-PCR analysis of C-terminal p73 splice variants in SCC15 cDNA. PCR was performed 
with primers in exons 8 and 14 of p73, (Zwahlen et al., 2000) using 1 ng of plasmids pcDNA3TAp73Į,
pcDNA3TAp73Ǆ, pcDNA3TAp73į and increasing amounts (2, 4, 6 or 8 l) of SCC15 cDNA as template. 
SCC15 cells were cultured at 37°C under 5% CO2 in DMEM/F12 (ratio 3:1) supplemented with 5% 
foetal bovine serum (HyClone) and 0.4 g/ml hydrocortisone (Sigma). RNA was isolated with TRIzol® 
(invitrogen) and in RT reactions Super-RT (Sphaero Q) was used as described by the manufacturers. 
PCR was carried out for 35 cycles (20 s, 94°C; 30 s, 53°C; 1 min, 72°C) after a 10 min 'hot start' at 
94°C and followed by final elongation at 72°C for 5 min. The reaction mixture contained 20 pmol of 
each primer, 1.25 units of AmpliTaqGOLDTM (Roche) and 1.5 mM MgCl2 in a total volume of 50 l. 
Control PCR products were run on a 1% agarose gel together with SCC15 cDNA PCR products. DNA 
was transferred to Hybond-N (Amersham) and hybridised with a p73 specific probe. (b) Sequence 
analysis of the p73ǆ splice variant: the 221 bp band (Figure 1a) was amplified, purified and 
sequenced. A portion of the sequence where exon 9 and 14 are connected is shown. (c) Schematic 
representation of p73 splice variants, including the p73ǆ variant. (d) RT-PCR analysis of C-terminal 
p73 splice variants in different cell types. HaCaT (immortal keratinocyte cell line) and HeLa cells 
(cervix carcinoma) were cultured in DMEM supplemented with 10% foetal bovine serum. HCT116 cells 
(colorectal carcinoma) were cultured in RPMI1640 supplemented with 10% foetal bovine serum 
(Hyclone). Primary human keratinocytes were isolated from foreskin derived from circumcision and 
grown in serum-free medium (KSFM; Gibco). Primary human fibroblasts were grown in DMEM/F10 in a 
1:1 ratio, supplemented with 10% foetal bovine serum (Hyclone). All cells were grown at 37°C under 
5% CO2. The controls for p73Į, p73Ǆ and p73į are the same as in Figure 1a. The control band for 
p73ǆ is the 221 bp PCR product of SCC15 cells. The p73 specific probe was made by digestion with 
Afl3 (exon 9) of a PCR product with 5'-GTCACCGGCAGGCAGAGC (exon 6) and 5'-
GCTCTCTTTCAGCTTCATCAGG (exon 10) on pcDNA3p73Į (the largest fragment was used as probe). 
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Samenvatting voor de leek 
De cel is de kleinste eenheid levend materiaal van het menselijk lichaam. 
Cellen zijn normaal gesproken zo klein dat ze afzonderlijk alleen met een microscoop 
te zien zijn. Omdat er veel verschillende organen in een menselijk lichaam aanwezig 
zijn, zijn er ook veel verschillende typen cellen. Zo bestaat bijvoorbeeld de lever uit 
andere cellen dan de dikke darm en die bestaat weer uit andere cellen dan de huid. 
Er is dus een grote verscheidenheid aan cellen en die cellen vormen verschillende 
weefsels. Ieder type cel vervult een bepaalde functie die meer of minder 
gespecialiseerd is. Dit komt doordat er in de verschillende celtypen verschillende 
eiwitten aangemaakt worden.
Eiwitten (ook wel proteinen genoemd) zijn de “werkpaarden” van cellen. Er 
zijn eiwitten die in alle celtypen nodig zijn, bijvoorbeeld om ervoor te zorgen dat de 
cellen kunnen delen, dat ze blijven leven etc. Ook zijn er eiwitten die alleen nodig 
zijn om bepaalde specifieke functies van een cel uit te voeren, deze komen alleen 
voor in de typen cellen waar ze nodig zijn. Zo zijn er eiwitten die bijvoorbeeld wel in 
levercellen voorkomen maar niet in huidcellen en vice versa. Eiwitten worden 
gemaakt in de cellen naar aanleiding van een soort beschrijving die vastgelegd ligt in 
het DNA. Het “alfabet” die de beschrijvingen vormen bestaat uit maar vier letters, A, 
C, G en T (basen). Een bericht noemt men een gen. In een cel worden constant 
verschillende signalen gegeven die ervoor zorgen dat de eiwitten die op dat moment 
in dat celtype nodig zijn gemaakt worden. Dit gebeurt dus volgens de beschrijving 
die in het DNA is vastgelegd.  
Er zijn nog enkele tussenstappen nodig om van DNA naar eiwit te gaan. 
Omdat het DNA intact moet blijven zodat er steeds opnieuw de noodzakelijke 
eiwitten aangemaakt kunnen worden, wordt er als tussenvorm (tussen DNA en eiwit) 
RNA gemaakt. RNA is vergelijkbaar met DNA en bestaat ook uit 4 letters A, C, G en U 
(in plaats van T) maar in tegenstelling tot DNA dat de informatie bevat om alle 
eiwitten te maken, bevat het RNA alleen de informatie die nodig is om één eiwit te 
maken. Als er veel van hetzelfde eiwit nodig is wordt er ook veel RNA van gemaakt. 
127
Het RNA is maar tijdelijk nodig (totdat het eiwit gemaakt is) en het is dus ook niet 
belangrijk voor een cel dat het intact blijft. Als er meer van nodig is kan er altijd 
meer gemaakt worden naar aanleiding van de code in het DNA.
Een gen bestaat naast delen die nodig zijn om een eiwit te beschrijven 
(exons) uit delen die niet gebruikt worden voor het eiwit (introns). Uit het RNA 
worden de introns verwijderd en de exons aan elkaar geplakt. Van sommige genen 
kunnen meerdere eiwitten gemaakt worden die enigszins van elkaar verschillen, dit 
komt omdat bij deze genen ook enkele exons uit het RNA geknipt kunnen worden. 
Een exon is dus een deel uit een gen dat gebruikt kan worden om een eiwit van te 
maken, maar het is niet altijd nodig om alle exons van een gen in het RNA te hebben 
om een bruikbaar eiwit te vormen. Naar mate er meer exons verwijderd worden, 
wordt het RNA steeds kleiner en het eiwit dat er van gemaakt wordt ook kleiner. Een 
eiwit waarbij ten opzichte van het RNA dat alle exons bevat, exons zijn verwijderd 
heet een (alternatieve) splice-variant.
Aminozuren zijn de bouwstenen voor eiwitten, er zijn 20 verschillende 
aminozuren. Ieder eiwit bestaat uit een aaneenschakeling van aminozuren, de 
meeste eiwitten bevatten er enkele honderden. De eigenschappen van een eiwit 
worden bepaald door de volgorde van de aminozuren, die wordt bepaald door de 
volgorde van de basen in het RNA en die wordt weer bepaald door de volgorde van 
de basen in het DNA. 
14-3-3 eiwitten zijn een familie van eiwitten die erg veel op elkaar lijken 
(homologen), omdat ze tijdens de evolutie niet veel veranderd zijn. 14-3-3 eiwitten 
komen in alle tot nu toe onderzochte eukaryotische organismen voor (o.a mensen, 
dieren, planten, en gist). Er zijn zeven menselijke 14-3-3 isovormen (eiwitten uit 
dezelfde genfamilie) namelijk 14-3-3 ǃ, Ǆ, İ, ǆ, ı, Ĳ en ǅ, die tot expressie komen (er 
wordt een eiwit gemaakt) van verschillende genen.  Door te binden aan andere 
eiwitten reguleren 14-3-3 eiwitten veel processen die belangrijk zijn in de celbiologie  
zoals; het doorgeven van signalen (signaal transductie), het aanmaken van RNA 
(transcriptie), apoptose of geprogrammeerde celdood (cellen die overbodig of 
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beschadigd zijn worden netjes opgeruimd door middel van een soort zelfmoord 
mechanisme), celcyclus regulatie (de celcyclus is nodig voor het delen van cellen en 
kan tijdelijk stilgelegd worden) en differentiatie (het ontwikkelen van cellen tot cellen 
die een gespecialiseerde taak hebben).
De algemene eigenschappen van 14-3-3 eiwitten worden besproken in 
hoofdstuk 1 (chapter 1). In dit hoofdstuk wordt extra aandacht besteed aan de 
rol van 14-3-3 eiwitten in keratinocyten (huidcellen) omdat een groot deel van het 
onderzoek in dit proefschrift gedaan is in, en betrekking heeft op, keratinocyten.
De laatste jaren worden er steeds meer verbanden gevonden tussen 14-3-3 
eiwitten en leden van de p53 genfamilie van transcriptiefactoren (eiwitten die 
transcriptie regelen). De p53 familie bestaat uit drie genen: p53, p63 and p73. 
Hoewel de p53 familie maar uit drie genen bestaat kunnen er veel meer dan drie 
verschillende eiwitten van gemaakt worden. Dit komt omdat er van p53, p63 en p73 
verschillende splice-varianten zijn. Deze eiwitten spelen een belangrijke rol bij 
processen in de cellen die ook geregeld worden door 14-3-3 eiwitten. 
Een introductie over de p53 familie en de directe verbanden tussen de p53 
familie en 14-3-3 eiwitten wordt gegeven in hoofdstuk 2. Hier is extra aandacht 
besteed aan de rol van p53 familieleden in keratinocyten. 
Omdat alle 14-3-3 eiwitten op een paar kleine verschillen na precies hetzelfde 
zijn, wordt er vaak van uit gegaan dat alle 14-3-3 eiwitten op een vergelijkbare 
manier werken. Desalniettemin zijn er toch aanwijzingen gevonden die er op wijzen 
dat er ook specifieke taken zijn voor de verschillende 14-3-3 isovormen.  
In hoofdstuk 3 is onderzocht of een van de isovormen, 14-3-3ǅ, specifieke 
taken heeft bij het ontstaan van kanker door in een keratinocyten cellijn (huidcellen 
die in een laboratorium gekweekt kunnen worden) 14-3-3ǅ uit te schakelen. Hier is 
gevonden dat als je 14-3-3ǅ uitschakelt, de cellen veel sneller in apoptose gaan na 
UV bestraling (er gaan meer cellen dood als je ze met UV licht bestraalt). Ook is 
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gevonden dat de cellen na uitschakelen van 14-3-3ǅ beter aan elkaar hechten. Bij 
kankercellen zijn deze twee eigenschappen vaak verloren gegaan. Dit wijst erop dat 
teveel 14-3-3ǅ ervoor zou kunnen zorgen dat een cel makkelijker een kankercel kan 
worden. Er is ook gevonden dat 14-3-3ǅ verhoogd aanwezig is in tumoren, deze 
vinding ondersteunt het idee dat als 14-3-3ǅ verhoogd in de cel aanwezig is dat de 
cel makkelijker omgevormd kan worden tot kankercel.
14-3-3 eiwitten kunnen van het cytoplasma (grofweg de cel behalve de kern) 
naar de kern (midden van de cel, hierin bevindt zich het DNA) gaan en vice versa. 
14-3-3 eiwitten bevinden zich voornamelijk in het cytoplasma van de cel, maar een 
klein gedeelte bevindt zich ook in de kern. Verschillen tussen de 14-3-3 isovormen in 
de snelheid van in en uit de kern gaan zouden kunnen bepalen of 14-3-3 isovormen 
specifieke biologische functies kunnen hebben. Daarom is in hoofdstuk 4 in 
verschillende soorten gekweekte zoogdiercellen onderzocht of er verschillen zijn 
tussen twee 14-3-3 isovormen, 14-3-3ǅ en 14-3-3ı, in de hoeveelheid eiwit in de 
kern en in het cytoplasma en of dat komt omdat de een sneller de kern in- of 
uitgaat. Hier is gevonden dat er een verschil is in de hoeveelheid 14-3-3ı in de kern 
ten opzichte van de hoeveelheid 14-3-3ǅ. Hoewel beide meer voorkomen in het 
cytoplasma dan in de kern is er naar verhouding meer 14-3-3ǅ in de kern dan 14-3-
3ı. Dat verschil komt doordat 14-3-3ı sneller de kern uit kan gaan dan 14-3-3ǅ,
terwijl ze beiden even snel de kern in gaan. 
 14-3-3ı wordt beschouwd als de meest afwijkende vorm van de menselijke 
14-3-3 eiwitten. In tegenstelling tot andere isovormen die in bijna alle celtypen tot 
expressie komen, komt 14-3-3ı eiwit alleen voor in epitheel cellen (bepaalde groep 
cel-typen, o.a keratinocyten) en deze isovorm heeft een specifieke rol in de 
differentiatie van keratinocyten (hoofdstuk 1). In andere celtypen zijn verbanden 
gevonden tussen p53 familieleden en 14-3-3 eiwitten, in het bijzonder 14-3-3ı
(hoofdstuk 2). In colorectale (darm) kankercellen wordt 14-3-3ı getransactiveerd (er 
wordt meer van gemaakt) door p53 na bestraling. Dit is nodig voor een goede arrest 
(cellen stoppen na bestraling tijdelijk met delen) in de G2 fase van de celcyclus (de 
celcyclus kent een aantal fasen, G2 is de laatste fase voor de celdeling).  
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In hoofdstuk 5 is een mogelijke rol onderzocht voor 14-3-3ı transactivatie of 
stabilisatie in door bestraling en p53 veroorzaakte G2 cel-cyclus arrest (een eiwit 
bestaat maar een korte periode, dan wordt het door de cel afgebroken. Als een 
bepaald eiwit langer nodig is dan normaal, kan het gestabiliseerd worden, het wordt 
dan minder snel afgebroken en daardoor blijft er meer van dit eiwit over in de cel). 
Dit is onderzocht in een p53 gereguleerde keratinocyten cellijn (deze cellijn heeft 
normaal geen p53 maar p53 kan wel aangezet worden). Hier is gevonden dat p53 
nodig is om cellen in een normale G2 arrest te laten komen na bestraling, maar dat 
dit in deze cellen niet veroorzaakt wordt doordat 14-3-3ı hoger tot expressie (meer 
RNA) komt of doordat het eiwit gestabiliseerd wordt. Dit verschil zou kunnen komen 
omdat 14-3-3ı bij keratinocyten erg belangrijk is voor differentiatie en omdat 
daardoor de rol bij cel-cyclus arrest wat minder duidelijk is dan bij andere celtypen. 
In hoofdstuk 6 is onderzocht of een dubbel GFP (groen fluorescerend) eiwit 
in met p53 getransfecteerde (transfectie is het tijdelijk inbrengen van DNA in cellen 
dat normaal gesproken niet voorkomt in de cel) cellen bijft zitten nadat de cellen zijn 
behandeld om het DNA te kleuren. Als p53 en een groen fluorescerend eiwit samen 
getransfecteerd worden kun je er vanuit gaan dat de groen fluorescerende cellen ook 
p53 tot expressie brengen, hierdoor is het makkelijker om de functie van p53 te 
onderzoeken. Het DNA moet gekleurd worden om te kijken in welke fase van de cel-
cyclus de cellen zich bevinden en of de cellen in apoptose gaan (deze processen 
worden gereguleerd door p53). Het is gebleken dat een enkel groen fluorescerend 
eiwit de cellen uit gaat na de behandeling om het DNA te kleuren. In dit hoofdstuk is 
gevonden dat een verdubbeling van het GFP eiwit inderdaad toereikend is om een 
GFP eiwit te maken dat in de cel blijft na DNA kleuring. Dit dubbele groene 
fluorescerende eiwit kan erg handig zijn bij verder onderzoek naar de precieze 
functie van p53, p53 familieleden en 14-3-3 eiwitten. 
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In het laatste hoofdstuk, hoofdstuk 7, is een veel gebruikte methode om 
verschillende p73 vormen (die o.a betrokken zijn bij transactivatie van 14-3-3ı) aan 
te tonen bestudeerd. Hier is gevonden dat deze methode wel gebruikt kan worden 
om te bepalen welke vormen van p73 er aanwezig zijn, maar dat je niet kunt 
bepalen in welke verhouding deze vormen voorkomen. Hierdoor blijkt het niet 
mogelijk om naar aanleiding van verschillen in expressie van p73 splice-varianten die 
gevonden zijn met deze methode uitspraken te doen over de rol van p73 varianten 
bij ziekten zoals bijvoorbeeld leukemie.
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Conclusions and future directions 
In recent years significant progress has been made in discovering targets of 
the 14-3-3 family of proteins, elucidating some of the molecular mechanisms that 
underlie 14-3-3 function and several important associations between 14-3-3 proteins 
and members of the p53 family have been revealed. It is evident that both families 
are key players in major cellular events such as the cell-cycle, apoptosis, 
differentiation and development and that the two families influence processes 
regulated by members of the other family. P53 family members regulate expression 
of genes involved in these events (either positively or negatively) and 14-3-3 proteins 
bind proteins involved in these processes (including p53 family members), thereby 
altering their characteristics. However, numerous questions regarding 14-3-3 
proteins, p53 family members and the relationships between the two families remain. 
Such as; why do 14-3-3 proteins and p53 family members express so many different 
isoforms or splice variants? In which cell-types and under which conditions are these 
variants expressed exactly? Does each protein exhibit specific biological functions? 
What is the degree of functional overlap between isoforms or splice-variants? How 
cell-type specific are the actions carried out by these proteins?
The data presented in this thesis contribute to answer these questions. In 
chapter 3 isoform-specific characteristics of 14-3-3ǅ have been revealed. A possible 
role for this protein in carcinogenesis was suggested because downregulation of 14-
3-3ǅ increased the propensity for DNA-damage induced apoptosis and increased cell-
cell contacts, two characteristics that are often lost in cancer cells. In addition, it is 
shown that 14-3-3ǅ protein is overexpressed in several tumors, which also indicates 
that it might be involved in tumorigenesis. In chapter 4, differences between 14-3-3ı
and 14-3-3ǅ in nucleocytoplasmic shuttling have been described. The difference in 
nucleocytoplasmic shuttling likely forms a basis for specialized biological functions of 
the 14-3-3 isoforms. In chapter 5, keratinocyte specific p53 regulated G2 cell-cycle 
arrest and the lack of a contribution for 14-3-3ı in this cell-type has been observed, 
whereas 14-3-3ı induction clearly plays a distinct role in G2 arrest in other cell-types. 
In chapter 6, an improved method for detecting p53 induced apoptosis by flow 
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cytometry is portrayed by expressing a duplicated GFP protein. This double GFP 
protein can be used for future research in the fields of 14-3-3 and p53. In chapter 7, 
a widely used method to detect and quantify p73 splice-variant expression is critically 
assessed. It turns out that, using this method it is not possible to accurately quantify 
p73 splice-variants. This observation might help future research to monitor p73 
splice-variant expression more accurately (by using alternative methods) and to 
prevent inaccurate statements about specific roles for particular p73 splice-variants in 
diseases such as leukemia.  
Although some information about the 14-3-3 and p53 families has become 
more clear in this thesis, much more research is needed to form a complete picture 
of how 14-3-3 isoforms and p53 family members collaborate in regulating major 
cellular processes. Fortunately, many researchers have noticed the scientific 
importance of 14-3-3 proteins and of the p53 family. For p53, the relevance for 
cancer biology has been acknowledged for decades. However, recent work has also 
suggested the involvement of the other p53 family members and the 14-3-3 proteins 
in human disease, mainly in cancer and neurological disorders and it is likely that 
other diseases will continue to come forward in the near future. Information 
concerning expression or activity of various 14-3-3 isoforms and p53 family members 
is likely to prove useful in the staging and prognostic evaluation, as well as the 
selection of treatment for certain cancers and possibly other diseases. Therapeutic 
approaches targeting 14-3-3 proteins are also under consideration. It has been 
proposed that targeting the 14-3-3 family as a whole might give optimal benefits in 
therapeutic applications. However, important isoform-specific 14-3-3 biological 
activities have been discovered, activities that sometimes even counteract the 
activities of other isoforms. As the knowledge of isoform-specific functions increases, 
approaches that target the activity of one isoform without interfering with the activity 
of the others might give straightforward therapeutic benefits. For example, as 
suggested in chapter 3, because 14-3-3ǅ downregulation reduces two cancer cell 
specific characteristics, this isoform might be a possible specific target in the future. 
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